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GEnERAl IntROduCtIOn 
Peripheral arterial disease (PAD) includes a range of arterial syndromes causing obstruction 
of the arteries that supply the brain, visceral organs and the limbs (1). This thesis will focus 
on PAD of the abdominal aorta and lower extremity arteries which are frequently affected by 
atherosclerosis.
PAD affects a large proportion of the adult population with a total disease prevalence ranging 
between 3% and 10% and increases up to 20% for persons over 70 years of age (2, 3). Risk 
factors for developing PAD are in general the same as for developing atherosclerosis and 
includes age, male gender, hypertension, diabetes mellitus, smoking, dyslipidaemia, family 
history and homocystemia (2, 3).The presence of a multitude of risk factors increases the risk 
for PAD (2).   
Clinical presentation can vary and depends on the severity of PAD. Repeated pain, discomfort 
or weakness during exercise of the lower legs which relieves after rest is typical for intermittent 
claudication (IC). Ischemic rest pain with or without ulceration or gangrene is seen in patients 
with critical limb ischemia (CLI). The diagnosis is based on an accurate history, non-invasive 
diagnostics (physical examination, ankle-brachial index (ABI) and duplex ultrasound) and, if 
indicated, followed by invasive diagnostics (contrast arteriography, Computed tomography 
arteriography and Magnetic resonance arteriography). A grading system, based on the 
Fontaine’s and Rutherford classification is used for classifying the severity of PAD (Table 1) (1, 
3, 4).
Although PAD is progressive in the pathological sense, its clinical course concerning the fate 
of the leg seems to be very stable (3). A major amputation is a relatively rare outcome in IC 
with amputation rates of only 1% and 3% over a 5-year period (3, 5). On the other hand, the 
fate of the leg is much more at risk at patients with CLI. The natural history of CLI is difficult to 
subscribe because most patients with CLI receive some form of treatment to retain the leg. 
In studies on selected patients with CLI having no treatment, 1-year amputation-rates varied 
between 16% and 54% (6, 7). 
Despite the risk that cardiovascular events are strongly correlated to the severity of PAD, 
the mortality of most patients were rarely a direct result of PAD itself (3, 8-10). Most of these 
patients will die from the complications of coronary artery disease, cerebrovascular disease 
or non-vascular causes (3). The management of patients with PAD is therefore complex 
and requires a multidisciplinary approach to reduce risk factors leading to progression of 
generalized atherosclerosis and relieve symptoms. 
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table 1. Rutherford’s categories of peripheral arterial disease (4).
Grade Category Clinical description Objective criteria
0 0 Asymptomatic Normal treadmill or reactive hyperemia test
I 1 Mild claudication Completes standard treadmill exercise; AP after exercise 
>50mmHg but at least 20 mmHg lower than resting value 
2 Moderate claudication Between category 1 and 3
3 Severe claudication Cannot complete standard treadmill exercise*; AP after 
exercise <50mmHg
II 4 Ischemic rest pain Resting AP<40mmHg, flat or barely pulsatile ankle of 
metatarsal PVR, TP < 30mmHg
III 5 Minor tissue loss: nonhealing ulcer, 
focal gangrene with diffuse pedal 
ischemia
Resting AP< 60mmHg, flat or barely pulsatile ankle or 
metatarsal PVR, TP<30mmHg
6 Major tissue loss: extended above 
transmetatarsal level, functional 
foot no longer salvageable 
Same as category 5
AP, ankle pressure; PVR, pulse volume recording; TP, toe pressure;*5 minutes at 2 mph (3.2 km/h) on a 12% incline.
The management of patients with less advanced stages of PAD is based on a restrained policy 
including preventative measures (e.g. statins and antiplatelet) and supervised walking exercise 
(11). However, invasive treatment options can be considered when supervised walking exercise 
fails or patients have more advanced stages of PAD like patients with CLI (1-3). Invasive treatment 
options include endovascular and surgical procedures. Although, endovascular procedures 
have positioned a prominent role in the modern vascular practice, surgical revascularisation 
might be indicated in selected patients with advanced stages of PAD (1-3).
Surgical revascularisation of infrainguinal lesions includes endarterectomy or bypass surgery 
(3). An endarterectomy might be considered in localized lesions. However, in complex- and 
mostly multilevel lesions a bypass is more suitable (femoropopliteal bypass (supragenicular 
or infragenicular) or femorocrural bypass) (3). The choice of conduit for peripheral bypass 
surgery can be an autologous- or a synthetic bypass (polytetrafluoroethylene (ePTFE) or 
polyethyleneterephthalate (Dacron®)). An autologous bypass is preferred over a synthetic 
bypass because of superior patency rates (12-18). In the absence of an adequate autologous 
vein, a synthetic bypass is a reasonable alternative. 
A potential problem using ePTFE grafts is the formation of myointimal hyperplasia at the level 
of the distal anastomosis which can lead to loss of patency (19). To resolve this problem, further 
refinements were introduced like a venous Miller cuff or St. Mary boot (12). As these procedures 
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added complexity and increased operation time to the original procedure, pre-cuffed ePTFE 
grafts were developed which demonstrated comparable patency-rates (20, 21). Midterm 
results of these bypasses demonstrated the pre-cuffed ePTFE grafts a reasonable alternative 
compared to autologous grafts (22).  
Besides the problems facing the choice of conduit in peripheral bypass surgery an even 
larger problem is seen in the treatment of patients with PAD. In general, surgical interventions 
performed in this particular patient group is associated with potentially severe adverse events 
influencing the outcome of peripheral vascular procedures. 
Improving outcome of provided care is an important topic in today’s medicine which is 
characterized by increased cost, individual patient awareness and the introduction of numerous 
diagnostic modalities and therapeutic strategies. Results can be used to detect shortcomings, 
evaluate new and old treatment modalities and initiate new research projects. Moreover this 
will increase transparency for physicians and hospitals.
AIm And thESIS OutlInE
The aim of this thesis is to evaluate the outcome of various clinical situations in the vascular 
clinic. The first part of this thesis evaluates the outcome of various vascular procedures. The 
focus of the second part of this thesis is on the prevention and treatment of SSI in patients with 
PAD. 
Outcome after peripheral vascular surgery
The ABI is an important parameter to determine the stage of PAD and patency (3, 4, 23, 24). 
Performing a manual measure is considered time-consuming and operator dependent. An 
automated ABI-device could potentially lead to more reliable measurements with potential 
time-savings. The applicability of such a device for diagnosing PAD is already demonstrated 
in the general population (25-29). Unfortunately, studies of such a device in postoperative 
ABI measures are lacking. In Chapter 2 the clinical applicability of an automated ABI-device 
is examined. Both manual and automated ABI measurements were compared in terms of 
reliability and time-performance.
As previously discussed, an autologous vein is the first choice of conduit for peripheral bypass 
surgery. Synthetic grafts are supposed to be inferior among others because of the change of 
anastomotic stenosis. Pre-cuffed ePTFE grafts are considered to mimic the natural state of the 
artery and to optimize flow at the distal anastomosis for improving patency rates. In Chapter 3 
the long-term outcome results of pre-cuffed ePTFE were compared to autologous vein bypass 
grafts used in patients with CLI. 
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Acute limb ischemia (ALI) is an acute and serious condition in which an artery of the lower 
limb is occluded. In general it is caused by an arterial embolism or thrombosis (30, 31). Rapid 
intervention is indicated to restore patency and limb salvage (23). Intervention options 
are surgical thromboembolectomy or intra-arterial thrombolysis. Thrombolysis has been 
gradually introduced since this is considered less invasive with comparable results as seen 
after thromboembolectomy (32-36). Insights on adverse events are lacking and need to be 
further specified. In Chapter 4, the outcome and adverse events after these two treatment 
options for patients with ALI are studied.
Prevention and treatment of SSI 
A surgical site infection (SSI) is defined by the centers for disease control (CDC) and includes 
superficial incisional-, deep incisional- and organ/space SSI (37). SSI’s are serious adverse 
events and can lead to reinterventions, morbidity and potential death after vascular surgery 
(38-40). Most importantly, SSI’s are considered to be one of the most preventable adverse 
events (41). Therefore, reduction of these SSI’s is very important in improving postoperative 
care of patients with PAD. This could be achieved by applying evidence based prevention 
protocols (42, 43). A bundle of care was developed by the Dutch hospital safety program to 
reduce these SSI’s. In Chapter 5 the implementation and effect of this bundle of care was 
evaluated. 
A groin incision is also a risk factor for SSI development (44, 45). Additionally, re-interventions 
are frequently performed throughout the clinical course of a vascular patient. Multiple 
groin incisions could potentially lead to a high incidence of adverse events, such as a SSI. 
Chapter 6 evaluates the effect of different groin incision intervals on SSI development after 
elective vascular procedures. 
Besides preventing the occurrence of SSI’s it is also important to manage a SSI. The management 
of a SSI in vascular surgery is challenging. Many treatment strategies have been suggested 
in the literature. Complete removal of the graft with extra-anatomic reconstruction, with in 
situ or antimicrobial-impregnated replacement, was traditionally considered as the ‘golden 
standard’ (46-48). More recently, the focus has shifted towards graft preservation and the 
previously mentioned strategies are considered to be associated with increased morbidity and 
mortality(49). Several successful graft preservation-strategies are mentioned like, muscle flaps 
and negative pressure wound therapies with or without muscle flaps (50-53). In Chapter 7, an 
observational study was performed of the treatment of all SSI after elective vascular surgery in 
patients with moderate to severe PAD in our clinic. 
Finally, Chapter 8 provides a summary of this thesis, a general discussion and future 
perspectives and Chapter 9 provides the summary and discussion in Dutch. 
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AbStRACt
An automated ankle-brachial index (ABI) device could lead to potential time-savings and more 
accuracy in ABI-determination after vascular surgery. This prospective cross-sectional study 
compared post-procedural ABIs measured by a manual method with ABIs of an automated 
plethysmographic method. Forty-two patients were included. No significant difference in 
time performing a measurement was observed (1.1 minutes, 95 % CI: -0.2 to +2.4; p = 0.095). 
Mean ABI with the automated method was 0.105 higher (95 % CI: 0.017 - 0.193; p = 0.020) 
than with the manual method, with limits of agreement of -0.376 and +0.587. Total variance 
amounted to 0.0759 and the correlation between both methods was 0.60. Reliability expressed 
as maximum absolute difference (95 % level) between duplicate ABI-measurements under 
identical conditions was 0.350 (manual) and 0.152 (automated), although not significant (p 
= 0.053). Finally, the automated method had a 34 percent points higher failure rate than the 
manual method. In conclusion based on this study, the automated ABI-method seems not to 
be clinically applicable for measuring ABI postoperatively in patients with vascular disease. 
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IntROduCtIOn 
The ankle-brachial index (ABI) is a widely used parameter for assessing the severity or 
progression of peripheral arterial disease (PAD) (1-4). Traditional manual measurements 
are carried out by a sphygmomanometer and a continuous wave Doppler. This method is 
considered difficult, time-consuming and operator dependent. An automated device could 
lead to potentially more reliable and easy to perform measurements. The applicability of such 
a device has already been described in the general population (5-9). Unfortunately clinical 
studies of such a device in postoperative ABI measures are lacking.
The objective of this study was to determine the clinical applicability of an automated ABI 
device. We compared the automated method with the manual method in terms of reliability 
(agreement and precision), time performance and failure rate in post procedural ABI 
measurement.
PAtIEnt And mEthOdS
Study population
A prospective cross-sectional study was performed between September 2013 and February 
2014. Patients aged 18 years or older were eligible for inclusion in this study after they 
underwent a vascular intervention. Patients with preoperatively proven non-compressible 
arteries (ABI ≥ 1.4 using the standard manual method) or patients unable to consent were 
excluded from this study. 
data collection 
Patient characteristics were acquired by questionnaires from the consent form and patient 
records. Ankle-Brachial indices (ABIs) were obtained the first postoperative day by a manual- 
and an automated plethsmographic method (Dopplex® ABIlity, Huntleigh diagnostics, Inc) 
on the surgical ward. All measures were performed two-sided (the right side first), first by the 
manual method followed by the automated method on subjects in supine position. To mimic 
the daily practice the manual ABIs were obtained by trained operators and the automated 
ABIs by registered nurses. Time measures were obtained using a stopwatch. 
Statistics
According to the protocol, 38 patients were needed to detect a correlation coefficient 
between the manual and automated method of 0.5 with 90 % power using a test size of 0.05 
(2-sided).
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time performance
Time management between both methods was tested using the paired t-test. 
Clinical applicability: agreement
The four repeated ABI-measurements (2 sides x 2 methods) were analyzed using linear mixed 
modeling. As fixed effects on ABI the mean difference between both methods and the effect 
of operation of the leg were estimated. The following random effects as components of total 
variance of ABI were considered: (i) between-subjects, (ii) side nested within subject, and (iii)) 
method nested within subject and side. The correlation coefficient between methods was 
calculated as the sum of the variance components (i) and (ii) and expressed as proportion of 
total variance (i) + (ii) + (iii). Limits of agreement (10) of the difference between both methods 
were calculated as the estimated fixed mean difference plus or minus 1.96 times the square 
root of twice the component (iii). 
Clinical applicability: Precision
Linear mixed modelling was used to estimate the within-subject variance of the ABI from its 
observed left-right differences under either method and to test the null hypothesis that this 
variance was the same under both methods using a likelihood ratio test. This variance is built 
up from random measurement variability along with within-subject variability based on almost 
two simultaneous measurements within a subject. Of the former linear mixed model analysis 
we took the variance component (ii) to subtract it from the variance obtained from this mixed 
model analysis, so that the remaining variance is supposed to be completely attributable to 
the method used and to stand for the intrinsic precision of the method. In order to better 
compensate for potential bias due to missing values of ABI-measurements, adjustment was 
made for the following fixed effects in this analysis: method (manual/automated), left leg 
operated, right leg operated, gender, age, Rutherford score > 2 and current smoker.
Clinical applicability: AbI failure
For analyzing the probability of a measurement method not producing a valid ABI-value a 
dichotomous failure indicator was defined. This failure outcome variable with four repeated 
measurements within a subject was analyzed through generalized linear modeling (GENLIN). 
The generalized estimating equations method was used to account for the correlation between 
the repeated measurements within a subject. GENLIN with an identity link function was used for 
testing the difference in failure rate between both measurement methods. Given the presence 
of a valid manual measurement, GENLIN was used with a logit link function for analyzing the 
automated failure rate depending on the following explanatory variables: gender, current 
smoker, side, if the leg was operated, age and the value of the manual ABI measurement.  
The clinical applicability of an automated ABI device   |   25
chapter
2
Statistical analyses were performed using the SPSS® software program version 20 (IBM, Armonk, 
New York, USA). P-values below 0•05 were considered to denote statistical significance. 
RESultS
time performance
A total of 42 patients were included in this study (Table 1). The automated method took 9.3 
minutes: 1.1 minutes shorter than the hand method (95 % CI: -0.2 to +2.4; p = 0.095).
table 1. Patient characteristics (n = 42).
Characteristic n (%)
Gender (male/female)
Male
Female
31 (74)
11 (26)
Risk factors
Age
Current smoker 
69 ±7.8
38 (90)
PAD (Rutherford class)
≤ 2
≥ 3
13 (31)
29 (69)
Procedure
Central
Peripheral 
15 (36)
27 (64)
Raw ABI data
Side method n mean ± Sd median (range)
Right Manual 40 0.81 ± 0.28 0.82 (0.30-1.61)
Automated 26 0.96 ± 0.26 0.96 (0.57-1.59)
Left Manual 41 0.81 ± 0.26 0.87 (0.36-1.38)
Automated 25 0.96 ± 0.29 0.86 (0.59-1.97)
Basic patient characteristics and study outcomes are presented as percentages, mean ± SD and median (range).
Clinical applicability: agreement
The automated method yielded a significantly higher mean ABI than the manual method 
(0.105, 95 % CI: 0.017 - 0.193; p = 0.020). Operation was associated with a significantly lower 
mean ABI (0.092; 95 % CI: 0.014 - 0.170; p = 0.022). After adjustment for these fixed effects, total 
variance was 0.0759 (ABI squared) and could be decomposed into: (i) 0.0302, (ii) 0.0156 and 
(iii) 0.0302. The correlation between both methods was 0.60. The limits of agreement of the 
difference (automated – manual) were -0.376 and +0.587 (Figure 1). 
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figure 1. Bland-Altman plot for comparing ABI-measurements taken with the automated- and the manual method, 
based on 49 non-missing observations (23 subjects with both sides and 3 subjects with 1 side). Mean diff erence and 
lower and upper agreement limits are restricted maximum likelihood estimates obtained from linear mixed modeling 
applied to all 42 subjects.
Clinical applicability: precision
The within-subject variance of ABI based on left-right diff erences of the automated method 
was 0.0186 compared to 0.0315 of the manual method. However, this diff erence was not 
signifi cant (chi-square with 1 df was 3.758, p = 0.053). Assuming the within-subject variance 
to be the same under both methods its estimate was 0.0273. Subtracting from these variances 
the pure within-subject component (ii) of 0.0156, we are supposed to get the intrinsic 
measurement variance (precision) of the methods: 0.0159 for the manual method and 0.0030 
for the automated method, or 0.0117 assuming them to be equal. The absolute diff erence 
between duplicate ABI-measurements using the manual method in a patient under exactly 
the same conditions was maximally 1.96×√(2×0.0159)=0.350 at the 95 % level. For the 
automated-method this maximum absolute diff erence was 0.152 and assuming identical 
variances of both methods was maximally 0.300.
Clinical applicability: AbI failure
The automated method had a failure rate of 34% points (95% CI: 18.7-49.5, p < 0.0005) higher 
than the manual method. The odds of the automated method not producing a valid ABI-value 
was signifi cantly infl uenced by gender and the level of the manually-measured ABI-value. The 
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failure odds ratio of females to males was 10.74 (95 % CI: 1.78 - 65.0; p = 0.010). A 0.1 point 
decrease in the manually-measured ABI-value was associated with a failure odds ratio of 1.24 
(95 % CI: 1.02-1.52; p = 0.035). These odds ratios were adjusted for the other variables in the 
model (current smoker, side, operation of the leg and age). 
dISCuSSIOn
This present study demonstrated a moderate similarity between the measurements from 
the automated method and those from the standard manual method, although this might 
as well reflect the moderate reproducibility of ABI-measurements anyhow. The automated 
method seemed to have a higher intrinsic precision than the manual method, although this 
conclusion just did not reach significance. Also no substantial and significant time-savings 
were reached with the automated method. At last but not at least, in our group of patients 
the automated method demonstrated a large proportion of failing measurements especially 
in females and with lower manually measured ABI levels. In conclusion, the Dopplex® ABIlity 
seems not clinically applicable in postoperative ABI-measurement. Future technological 
refinements are necessary and this should be performed by independent researchers in an 
independent laboratory.
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AbStRACt
Objective: Long-term results of pre-cuffed expanded polytetrafluoroethylene (ePTFE) grafts 
used for peripheral bypass surgery are lacking. The aim of this study was to obtain the long-
term outcomes of pre-cuffed ePTFE grafts compared with autologous saphenous vein (ASV) 
grafts used in patients with peripheral arterial disease (PAD).
methods: A single-institution retrospective study of pre-cuffed ePTFE and ASV graft 
performances in patients with PAD was undertaken between January 2004 and December 
2012. Five-year primary patency, secondary patency, and limb salvage rates were determined 
by Kaplan-Meier analyses.
Results: A total of 467 bypass grafts were included in this study (169 pre-cuffed ePTFE grafts 
and 298 ASV grafts). Secondary patency rates of ePTFE vs ASV at 1 and 5 years, respectively, 
were as follows: for 134 supragenicular femoropopliteal bypasses, 60% and 27% vs 89% and 
85% (P < .05); for 190 infragenicular femoropopliteal bypasses, 40% and 25% vs 86% and 79% 
(P < .05); and for 84 femorocrural bypasses, 30% and 14% vs 50% and 50% (P < .05). Five-year 
limb salvage rates of ePTFE vs ASV for supragenicular femoropopliteal bypasses were 82% 
vs 94% (P = .16); for infragenicular femoropopliteal bypasses, 41% vs 92% (P < .05); and for 
femorocrural bypasses, 43% vs 64% (P = .06).
Conclusions: ASV bypasses are still the first-choice conduit in peripheral bypass surgery 
performed in patients with PAD. Pre-cuffed ePTFE bypasses are acceptable alternatives in the 
absence of adequate autologous vein.
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IntROduCtIOn
The autologous saphenous vein (ASV) is widely accepted as the first choice of conduit in 
peripheral bypass surgery. Because of impaired quality or previous use of the ASV for vascular 
or cardiac surgery, synthetic grafts like expanded polytetrafluoroethylene (ePTFE) have been 
demonstrated to be acceptable alternatives. Especially in supragenicular femoropopliteal 
bypass surgery, patency rates are acceptable for ePTFE bypass reconstruction (1-3). Patency 
rates of infragenicular femoropopliteal and femorocrural bypasses are still worse in ePTFE 
grafts compared with ASV (4). 
Adjunctive procedures like the venous Miller cuff and St. Mary boot, which mimic the natural 
state and improve distal flow dynamics, have been developed to improve ePTFE patency rates 
(5, 6). As these procedures added complexity and increased operation time to the original 
procedure, pre-cuffed ePTFE grafts were developed. These bypasses demonstrated patency 
rates comparable to those of ePTFE grafts refined with venous cuffs (7, 8). 
As mentioned in an earlier report from our clinic (9), we preferably use ASV grafts for peripheral 
bypass surgery in patients with peripheral arterial disease (PAD). If that is not applicable, a pre-
cuffed ePTFE Dynaflo graft (Bard Peripheral Vascular Inc, Tempe, Ariz) is used in supragenicular 
femoropopliteal bypass reconstructions, and a pre-cuffed ePTFE Distaflo graft (Bard Peripheral 
Vascular Inc) is used in infragenicular femoropopliteal bypass and femorocrural bypass 
reconstructions.
During the past decades, technical development of endovascular procedures like percutaneous 
transluminal angioplasty has led to an increased use of minimally invasive treatment 
options for patients with less severe stages of PAD and less complex arterial lesions(10-12). 
This has shifted the indication for peripheral bypass surgery toward a more severe stage of 
PAD. Previously reported patency and limb salvage rates are potentially not applicable for 
contemporary clinics (2). Our previous report demonstrated acceptable midterm results of 
pre-cuffed ePTFE grafts with respect to limb salvage(9). However, the long-term results of 
pre-cuffed ePTFE grafts are lacking. The aim of this study is to analyse long-term results up to 5 
years of pre-cuffed ePTFE and ASV grafts in patients with moderate to severe PAD, with special 
attention to limb salvage and adverse events.
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mEthOdS
Study design
Between January 2004 and December 2012, all consecutive patients having peripheral bypass 
surgery for moderate to severe PAD (Rutherford class 3-6) were retrospectively reviewed. 
Inclusion criteria were use of autologous venous or pre-cuffed ePTFE bypass grafting. Patients 
who underwent peripheral vascular revascularization by combined venous or other bypass 
graft material (standard PTFE or Dacron®) were excluded from analyses. 
Basic characteristics like age, gender, Rutherford classification, diabetes, arterial hypertension, 
and smoking status were retrieved from patients medical charts. Previous vascular 
interventions and data from surgical work up like ankle-brachial index (ABI), TASC-scores and 
number of open crural arteries, were recorded. Patency rates were determined by information 
from medical charts, such as physical examination, medical imaging, and laboratory results. 
Death was confirmed through the COMPET&T database from the company T&T Eindhoven.
Before surgery, patient workup included ABI, treadmill test, and magnetic resonance 
angiography or, when that was not applicable, digital subtraction angiography. Autologous 
bypass grafting was intended in all patients. Pre-cuffed ePTFE bypass grafts were considered 
when the ASV or lesser saphenous vein in both the ipsilateral and contralateral leg were 
absent or unsuitable (diameter <2 mm) for bypass grafting. This was determined by standard 
ultrasound evaluation (13) or, if ultrasound was inconclusive, on the basis of perioperative 
exploration. 
Surgery was performed under general or spinal anesthesia. Before clamping, all patients 
received an intravenous dose of 5000 international units of heparin. All anastomoses were 
made end to side. Autologous bypass grafting was performed with either deep-tunneled 
reversed or in situ techniques. Pre-cuffed Dynaflo grafts were used in supragenicular 
femoropopliteal bypasses, and pre-cuffed Distaflo or pre-cuffed minicuff Distaflo grafts 
were used in infragenicular femoropopliteal and femorocrural bypasses. Routine Doppler 
assessment was performed before wound closure.
Based on the Dutch Bypass Oral Anticoagulants or Aspirin (BOA) trial, postoperative 
anticoagulant administration (acenocoumarol) was initiated for a 2-year period after 
autologous bypass surgery, followed by acetylsalicylic acid (ASA) (14, 15). After pre-cuffed 
ePTFE bypass grafting, ASA was administered. No warfarin was administered after any of the 
procedures. Follow-up after ASV bypass surgery included routine duplex ultrasound and ABI 
at 3 months, 6 months, 1 year, and 2 years after the initial procedure, followed by ABI every 
subsequent 2 years. Follow-up after ePTFE bypass surgery was restricted to duplex ultrasound 
and ABI examination at 3 months, 1 year, and 2 years after the initial procedure (9, 16). ABI 
was measured every subsequent 2 years. All other interim duplex ultrasound examinations 
The current position of pre-cuffed ePTFE bypass grafts in peripheral vascular surgery   |   35
chapter
3
were performed after suspicion of graft-related problems. Interventions were performed 
on the basis of high-grade stenosis (peak systolic velocity ratio > 2.5); evidence comprised 
flow in the bypass or graft thrombosis. The primary end point was graft patency after 5 years, 
divided into primary patency, primary assisted patency, and secondary patency according to 
the definition of Rutherford (17). Patency dates were recorded at the last visit at which the 
bypass was proved open. The definition of limb salvage was freedom from having a major 
amputation in patients who had critical ischemia (Rutherford class 4-6). 
Adverse events per procedure were recorded until 1 month after discharge of the primary 
procedure and defined according to the Association of Surgeons of the Netherlands. Total 
follow-up was performed until October 2013.
Statistical analysis. 
Statistical analysis was performed with SPSS 20.0 software (SPSS Inc, Chicago, Ill). Continuous 
variables were analyzed by a Student t-test, and categorical variables were analyzed by c2 
analyses and Fisher exact tests for smaller samples. Survival rates were produced with Kaplan-
Meier survival curves with log-rank tests for comparison. Results were compared with a P 
value < .05 to show significant differences.
RESultS
A total of 467 peripheral bypass grafts were included between January 2004 and December 
2012. Basic patient characteristics are listed in Table I. In general, the indications for peripheral 
bypass grafting were based on moderate to severe PAD. Of these 467 grafts, 169 ePTFE grafts 
(36%) and 298 ASV grafts (64%) were used. Significantly more patients with Rutherford class 
3 had undergone venous grafting compared with ePTFE (28% vs 15%; P < .05). In the ePTFE 
group, significantly more procedures were a repeated procedure (31% vs 11%; P < .05).
Preoperative patient characteristics are listed in Tables 2 and 3. In more than 50% of the 
bypasses, the indication for surgery was based on multiple femoropopliteal lesions (TASC D: 
ePTFE 62% and venous 60%). In two patients, pre-procedural information about open crural 
arteries was missing. Significantly more ePTFE bypasses were placed in legs having one open 
crural artery (59 ePTFE [35%] vs 79 ASV grafts [27%]; P < .05).
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table 1. Patient basic characteristics.
Characteristics total
(n=467)
Pre-cuffed ePtfE
(n=169)
ASV
(n=298)
P-value
mean age (range) 73,0 (41,0-92,7) 70,1 (36,8-96,5)
Gender
Male
Female
Risk factors
History of smoking
Diabetes
Hypertension
Rutherford classification
Rutherford 2
Rutherford 3
Rutherford 4
Rutherford 5, 6
Distal anastamosis
Supragenicular
Infragenicular
Crural
Primary/redo status
108 (64%%)
61 (36%)
125 (74%)
66 (40%)
109 (72%)
1 (1%)
25 (15%)
69 (41%)
74 (44%)
45 (27%)
67 (39%)
57 (34%)
52 (31%) 
209 (70%)
89 (30%)
230 (77%)
112 (38%)
187 (63%)
4 (1%)
82 (28%)
101 (34%)
112 (38%)
89 (30%)
123 (41%)
86 (29%)
32 (11%)
0,17a
0,43a
0,72a
0,49a
0,66 b
0,00a
0,13a
0,19a
0,46a
0,73a
0,27a
0,00a
ASV, Autologous saphenous vein; ePTFE, expanded polytetrafluoroethylene. ePTFE = expanded polytetrafluoroethylene; 
aPearson χ2-test; bFisher’s Exact Test.
table 2. Pre-operative patient characteristics.
total
(n=467)
Pre-cuffed ePtfE
(n=169)
ASV
(n=298)
P-value
TASC II femero-popliteal 
TASC A
TASC B 
TASC C
TASC D
Number of open crural arteriesc
3
2
1
0
3 (2%)
8 (5%)
53 (31%)
105 (62%)
46 (28%)
52 (31%)
59 (35%)
10 (6%)
6 (2%)
15 (5%)
97 (33%)
180 (60%)
100 (34%)
109 (37%)
79 (27%)
10 (3%)
1,00b
0,89a
0,79a
0,71a
0,18a
0,24a
0,05a
0,18a
ASV, Autologous saphenous vein; ePTFE, expanded polytetrafluoroethylene; TASC II, TransAtlantic Inter-Society 
Consensus Document II. aPearson χ2-test. bFisher exact test. cTwo missing bypasses for number of open arteries.
table 3. Percentages pre-cuffed ePTFE vs vein uses in the total study population.
Characteristics Pre-cuffed ePtfE ASV
Supragenicular (%) 45 (34%)  89 (66%)
Infragenicular (%) 67 (34%) 123 (66%)
Femerocrural(%) 57 (40%)   86 (60%)
ASV, Autologous saphenous vein; ePTFE, expanded polytetrafluoroethylene.
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Patency
Primary, primary assisted, and secondary patency rates in supragenicular and infragenicular 
femoropopliteal bypass grafts and femorocrural bypass grafts were in favor of ASV compared 
with ePTFE (Table 4). Five-year primary patency rates for ePTFE and ASV in supragenicular 
femoropopliteal bypass grafts were 25% and 60%; in infragenicular femoropopliteal bypass 
grafts, 8% and 54%; and in femorocrural bypass grafts, 9% and 50% (P < .05). Secondary 
patency rates were also in favor of ASV compared with ePTFE in all three anatomic sites. Five-
year secondary patency rates for ePTFE and ASV in supragenicular femoropopliteal bypass 
grafts were 27% and 85%; in infragenicular femoropopliteal grafts, 25% and 79%; and in 
femorocrural grafts, 14% and 50% (P < .05) (Table 4; Figs 1-3).
table 4. Patency rates expressed in percentages (%).
Characteristics Pre-cuffed ePtfE ASV
mean follow-up months (range) 28,8 (<1-112) 36,1 (<1-116)
Anatomic site Patency 1 year 2 years 5 years 1 year 2 years 5 years
Supragenicular Primary 56d 42d 25d 68d 60d 60d
Primary assisted 59d 45d 27d 87d 82d 82d
Secondary 60d 47d 27d 89d 85d 85d
Infragenicular Primary 34d 18d 8d 65d 60d 54d
Primary assisted 36d 22d 11d 79d 77d 74d
Secondary 40d 31d 25d 86d 81d 79d
Femorocrural Primary 24 24 9 39 39 18
Primary assisted 24d 24d 9d 45d 43d 30d
Secondary 30d 27d 14d 50d 50d 50d
ASV, Autologous saphenous vein; ePTFE, expanded polytetrafluoroethylene. Patency rates are expressed in 
percentages. aLog-rank, P < .05. All standard errors were less than 10%.
limb salvage and survival
Limb salvage was based on 356 patients suffering from critical limb ischemia (Rutherford class 
4-6). Limb salvage after 5 years was significantly higher in the ASV group (82% vs 49%; P < .05). 
No significant difference was seen in limb salvage for supragenicular femoropopliteal (82% vs 
94%; P = .16) and femorocrural (43% vs 64%; P = .06) bypasses.
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figure 1. Kaplan-Meier curves representing secondary patency rates of autologous saphenous vein (ASV) and expanded 
polytetrafluoroethylene (ePTFE) supragenicular femoropopliteal bypasses (log-rank, P = .000). SE, Standard error. 
figure 2. Kaplan-Meier curves representing secondary patency rates of autologous saphenous vein (ASV) and 
expanded polytetrafluoroethylene (ePTFE) infragenicular femoropopliteal bypasses (log-rank, P = .000). SE, Standard 
error. 
ePTFE # at Risk
SE
ASV # at Risk
SE
67 21 14 10 8 4 3
.00 .064 .064 .063 .063 .064 .064
123 88 70 52 39 31 23
.00 .033 .038 .041 .041 .041 .041
ePTFE # at Risk
SE
ASV # at Risk
SE
45 21 13 8 3 3 3
.00 .076 .083 .087 .099 .099 .099
89 58 46 37 27 20 16
.00 .036 .036 0.044 0.044 0.044 0.044
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figure 3. Kaplan-Meier curves representing secondary patency rates of autologous saphenous vein (ASV) and 
expanded polytetrafluoroethylene (ePTFE) femorocrural bypasses (log-rank, P = .012). SE, Standard error. 
figure 4. Kaplan-Meier curves representing limb salvage of autologous saphenous vein (ASV) and expanded 
polytetrafluoroethylene (ePTFE) bypasses (log-rank, P = .000). SE, Standard error. 
ePTFE # at Risk
SE
ASV # at Risk
SE
143 65 47 35 26 17 11
.00 .042 .046 .049 .054 .054 .059
213 144 110 87 64 45 34
.00 .024 .029 .029 .029 .029 .029
ePTFE # at Risk
SE
ASV # at Risk
SE
57 13 10 5 3 3 1
.00 .068 .067 .067 .072 .072 .075
86 31 19 15 10 7 5
.00 .058 .059 .059 .059 .059 .059
40   |    Chapter 3
table 5. Limb salvage expressed in percentages (%).
Characteristics Pre-cuffed ePtfE ASV
distal anastomosis 1 year 2 years 5 years 1 year 2 years 5 years
Supragenicular 82 82 82 94 94 94
Infragenicular  69a  59a  41a  95a  92a  92a
Femerocrural 54 48 43 72 64 64
Overall  66a  60a  49a  86a  82a  82a
ASV, Autologous saphenous vein; ePTFE, expanded polytetrafluoroethylene. Limb salvage rates are expressed in 
percentages. aLog-rank, P < .05.
Limb salvage was significantly higher in the ASV group for infragenicular femoropopliteal 
bypasses compared with ePTFE grafts (92% vs 41%; P < .05) (Table 5; Fig 4). For 5-year survival, 
see Fig 5. After 5 years, significantly more patients were still alive after ASV bypass graft 
procedures compared with pre-cuffed ePTFE bypass graft procedures (ePTFE 56% vs ASV 67%; 
P < .05).
figure 5. Kaplan-Meier curves representing survival of autologous saphenous vein (ASV) and expanded 
polytetrafluoroethylene (ePTFE) bypasses (log-rank; P ¼ .02). SE, Standard error.
 
128 102 90 86 78 76 71
.00 .036 .040 .042 .043 .043 .044
271 234 217 207 199 189 182
.00 .021 .024 .026 .027 .028 .029
ePTFE # at Risk
SE
ASV # at Risk
SE
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Adverse events
As listed in Table VI, a total of 159 adverse events were registered after all primary procedures. 
Significantly more adverse events were observed after ePTFE compared with ASV bypass 
grafting (40% vs 30%; P < .05). No particular adverse event was significantly different between 
both groups. Most adverse events were related to the surgical procedure (surgical site 
infections: ePTFE 18%, ASV 17%; hemorrhages: ePTFE 11%, ASV 15%; compartment syndromes, 
ePTFE 1%, ASV none). The 30-day mortality was 3% for both groups. 
table 6. Adverse events occurred after primary procedure.
Characteristics total
(n=467)
Pre-cuffed ePtfE
(n=169)
ASV
(n=298)
P-value
Adverse events per procedure
Minor Events
Urine tract infection
Bladder retention
Decubitus
Surgical Events
Wound infection
Wound necrosis
Seroma
Hemorrhages
Compartment syndrome
Systemic
Myocardial infarct
Decord compression
Arrhythmia 
Hypovolemic shock
Pneumonia
Respiratory insufficiency
CVA
Neurological
Acute renal failure
Diarrhea
Ileus
Delier
Mortality
Within 30 days
70 (41%)
4 (2%)
2 (1%)
-
30 (18%)
3 (2%)
4 (2%)
11 (7%)
2 (1%)
4 (2%)
6 (4%)
2 (1%)
-
5 (3%)
5 (3%)
1 (1%)
2 (1%)
2 (1%)
3 (2%)
-
5 (3%)
5(3%)
89 (30%)
2 (1%)
2 (1%)
4 (1%)
50 (17%)
2 (1%)
3 (1%)
15 (5%)
-
8 (3%)
5 (2%)
4 (1%)
1 (0%)
4 (1%)
2 (1%)
2 (1%)
3 (1%)
5 (2%)
2 (1%)
1 (0%)
4 (1%)
8 (3%)
0,01a
0,20b
0,62b
0,30b
0,79a
0,36b
0,26b
0,53a
0,13b
0,84a
0,22b
1,00b
1,00b
0,30b
0,10b
1,00b
1,00b
1,00b
0,36b
1,00b
0,30b
0,86a
ASV = Autologous saphenous vein; ePTFE = expanded polytetrafluoroethylene; CVA = cerebrovascular accident. 
aPearson χ2-test; bFisher’s exact test.
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dISCuSSIOn
This study confirms ASV grafts to be the first choice of conduit in peripheral bypass surgery, 
with better 5-year patency and limb salvage rates compared to pre-cuffed ePTFE grafts (2, 
18). When an ASV graft is not applicable, pre-cuffed ePTFE grafts used in supragenicular 
femoropopliteal bypass surgery demonstrate acceptable short-term patency results and 
5-year limb salvage rates comparable to those of ASV grafts. Pre-cuffed ePTFE grafts used 
for infragenicular femoropopliteal and femorocrural bypass grafting demonstrate poor short- 
and long-term results but are considered acceptable alternatives when ASV grafts are not 
available.
Many reports demonstrating acceptable midterm results are published in the literature (9, 
19, 20). Also, our previous report demonstrated acceptable short-term outcome of ePTFE 
bypass grafts especially with respect to limb salvage (9). The present study, by demonstrating 
comparable results, did not change this conclusion.
A recently published study of long-term results from pre-cuffed ePTFE vs ASV bypasses 
demonstrated better 5-year secondary patency rates of infragenicular femoropopliteal 
bypasses of 51% vs 84% compared with our results (18). Limb salvage after infragenicular 
femoropopliteal bypasses also demonstrated better results (79.4% vs 83.3%; not significantly 
different). The 5-year rates of pre-cuffed femorocrural ePTFE vs ASV grafts for secondary 
patency (22.1% vs 50.6%) and limb salvage (22.1% vs 50.6%) were comparable to our results. 
The choice of conduit could be a potential explanation for these differences because this was 
based on the preference of the attending surgeon in their series.
To improve patency rates, heparin-bound ePTFE (HePTFE) grafts were introduced. Daenens 
et al (16) demonstrated impressive patency rates of below-knee HePTFE bypasses, with 
equal primary patency rates for HePTFE and vein grafts (83% vs 80%). In later reports, the 
superiority of HePTFE grafts was invalidated by no significant difference between HePTFE and 
ePTFE grafts (21, 22). The explanation of this difference could be the large number of HePTFE 
bypasses (69%) included in the Daenens study, in contrast to the small number of ASV grafts 
(31%).
Our antithrombotic regimen was based on the BOA trial demonstrating that the use of 
anticoagulants for more than 2 years after ASV bypasses does not attain better patency rates 
(14). The use of anticoagulants after synthetic bypass grafting did not attain better patency 
rates compared with ASA monotherapy and resulted in more postoperative adverse events 
like major bleedings. On this basis, we assume that our antithrombotic regimen had no 
attributable effect on our patency rates. 
Adverse events until 1 month after discharge were registered from medical charts. Most 
events were wound related but not significantly different between both procedures. Because 
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most procedures were performed on patients with a mean age of more than 70 years, the 
probably underestimated prevalence of postoperative delirium (3%) is therefore worth 
mentioning. Postoperative prevalence of delirium up to 42% is known in the literature (23) 
and because of the consequences like prolonged recovery time, extra nursing care, longer 
intensive care unit stay, and higher complication rates (24) this could be an interesting topic 
for future prospective studies. 
Pre-cuffed ePTFE grafts were frequently used in patients with an advanced stage of PAD and 
also in repeated procedures, demonstrating that pre-cuffed ePTFE grafts were used in a more 
disadvantaged situation compared with ASV grafts. This could be an explanation of why we 
obtained these worse patency outcomes after these bypass grafts. This was also demonstrated 
in previous reports in which ePTFE demonstrated obligatory results because of the absence of 
an autologous vein (4). This should be taken into account in interpreting our results. 
Our study has limitations because of its retrospective design, which should be considered 
in interpreting the results. We acknowledge that because of multiple medical problems 
related to severe PAD, it was difficult to retain a large patient population during 5 years of 
follow-up. Five-year results, especially for femorocrural bypasses, were therefore based on less 
patients. We also acknowledge that there could be an underestimation of the total amount 
of adverse events during follow-up because we registered only the adverse event from the 
primary procedure. Adverse events after secondary procedures were not registered but are 
also important to be taken into account because these procedures will happen during follow-
up. Finally, our results were obtained from a large population of peripheral bypasses based on 
a patient population with moderate to severe PAD.
COnCluSIOn
In a population with more patients suffering severe PAD, ASV bypass grafts are the first choice 
of conduit. Pre-cuffed ePTFE bypasses used in infragenicular femoropopliteal and femorocrural 
bypass surgery are still acceptable alternatives in the absence of adequate autologous vein. 
For improvement of the patency rates in infragenicular femoropopliteal and femorocrural 
bypasses, future research has to be performed on alternative procedures or other bypass 
conduits. 
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AbStRACt
background: To assess the outcome and the occurrence and consequences of adverse 
events (AEs) after treatment of acute limb ischemia (ALI).
methods: Retrospective analysis on intra-arterial thrombolysis (group I) and 
thromboembolectomy (group II). Outcome measures were primary patency and limb salvage 
rates. AEs and consequences were registered during admission and 30 days after discharge.
Results: A total of 238 procedures were included (group I, 173 vs. group II, 65). The primary 
patency (P = 0.144) and limb salvage rates (P = 0.166) were not significantly different between 
both groups. A total of 195 AEs were registered. Most AEs were procedure related and resulted 
in surgical reintervention (77% vs. 76%). Some AEs resulted in irreversible physical damage 
(15% vs. 25%) and death (6% vs. 12%).
Conclusions: Both, intra-arterial thrombolysis and thromboembolectomies are adequate 
therapies; however, they result in a wide variety of AEs resulting in serious morbidity and even
death.
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IntROduCtIOn
Acute limb ischemia (ALI) generally occurs after an acute arterial occlusion of an extremity 
mostly due to an arterial embolism or thrombosis(1, 2). Accurate and adequate clinical 
recognition is essential to improve limb salvage, reduce morbidity, mortality and to maintain 
quality of life(3). 
Surgical thromboembolectomy has been the standard procedure for ALI for a long period 
(4). Since the last 2 decades, intra-arterial thrombolysis demonstrated comparable outcome 
results to thromboembolectomy(5-9) and has become the preferred choice of treatment in 
patients with ALI(3).
Arguments for thrombolysis instead of surgery were the less invasive character of the 
treatment with decreased risk of perioperative adverse events (AEs). However, reports about 
post-procedural AEs of both procedures are in our opinion scarce, outdated and mostly 
focussed on haemorrhages (10, 11). 
AEs are one of the key issues in outcome measurement resulting in prolonged hospital stay 
and/or reinterventions, eventually leading to increased health care costs (12). Outcome 
measures are important since intra-arterial thrombolysis is considered to be a relatively safe 
procedure, although the indications for intra-arterial thrombolysis and thrombectomy are 
different. 
The aim of this study was to assess the occurrence and consequences of AEs after both 
procedures. Secondary outcome parameters were patency and limb salvage. 
mAtERIAl  And mEthOdS
Patients
All consecutive procedures performed in patients with ALI were retrieved from a database 
based on operation codes corresponding to intra-arterial thrombolysis or thrombectomies 
between January 2008 and December 2012. The included procedures were divided into two 
groups; group I: patients treated with intra-arterial thrombolysis, and group II: patients treated 
with thromboembolectomy. Combined procedures (thrombolysis/thrombectomy followed 
by other vascular procedures), procedures performed within 6 weeks after the last elective 
vascular procedure or procedures performed on patients with more than 6 weeks complaints 
were excluded from this survey (Figure 1). 
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Group I
173
figure 1. Flow-chart representing procedure selection of 376 codes for intra-arterial thrombolysis/
thromboembolectomy (January 2008 – December 2012); (Group I = intra-arterial thrombolysis; group II = 
thromboembolectomy).
Risk factors and comorbidities 
Cardiovascular risk factors, comorbidity and clinical categories of ALI were registered 
according to the Trans-Atlantic Inter-Society Consensus Document on Management of 
Peripheral Arterial Disease (TASC) and the society of vascular surgery/North American Chapter 
of the International Society for Cardiovascular surgery (SVS/ISCVS) guidelines(13, 14). The 
American Society of Anaesthesiologists (ASA)-score and past-history of active malignancy 
and abdominal aneurysms were also collected.
376 
thromboembolectomy / trombolysis
Group II
65
7 combined
with other
vascular
procedures
7 occlusions
after
endovascular
procedures
1 procedure
because of
direct referral
43 combined
with other
vascular
procedures
18 occlusions
after
endovascular
procedures
9 patients
>6 weeks
complains
53 occlusions
due to 
operation
<6 weeks
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Procedure
Procedural indications for intervention were based on the TASC and SVS/ISCVS guidelines(13, 
14). Thromboembolectomies were performed according to standard vascular procedures. 
Thrombolysis was performed according to the hospitals standards (Appendix 1). Post-
procedural success was defined as increased run-off after intervention. In general, all patients 
received acenocoumarol//Sintrom® until the target International Normalized Ratio (INR) was 
achieved (INR: 2.5 and 3.5) after all procedures. Thereafter heparin infusion was terminated. 
follow up and outcome 
In general, anticoagulant therapy was terminated after 6 months of the initial procedure, 
unless other indications were present. To determine patency, patients underwent clinical 
examination, duplex ultrasound examination (DUE) and ankle brachial index (ABI) during 
routine examination. Patency -, limb salvage rates were determined according to TASC- and 
SVS/ISCVS guidelines (13, 14). Patency dates were recorded at the last visit at which the artery 
was proven to be open. The definition of limb salvage was freedom from having a major 
amputation after the procedure. Death was confirmed through the COMPET&T database from 
the company T&T Eindhoven, the Netherlands. 
Adverse events 
All adverse events (AEs) were registered during follow up from patient records. An AE was 
defined by the following general definition: “a condition or event, unfavorable to the patient’s 
health or treatment causing unintentional damage or requiring a change in therapeutic policy 
or additional treatment, which occurred during admission or within 30 days after discharge 
or transferee to another department. The intended result of treatment, the likelihood of the 
adverse outcome occurring, and the presence or absence of a medical error causing it, is 
irrelevant in identifying an adverse outcome”. This definition was confirmed by the Association 
of Surgeons of the Netherlands (ASN) and has been chosen with the explicit aim of excluding 
subjective judgment on cause and effect, and right or wrong (12, 15-18). Also the consequences 
of all AE were registered based on their severity. The potential consequences of the AEs were 
divided into: minor complication, no long-term consequence, additional medication or 
transfusion, surgical reoperation, prolonged hospital stay and irreversible damage (12, 19). 
Registration and statistical analysis
Patient information was registered in an electronic patient file used for all patients during their 
admission intake. Statistical analyses were performed through a computerized software package, 
using IBM SPSS 20.0. Kaplan-Meier-survival methods were used to calculate the time curve of the 
cumulative patency -, limb salvage - and 1-year mortality rates determined at regular intervals 
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after the initial procedure. Log-rank tests were used to compare the results of both groups. 
Univariate analysis was performed using Chi-square, Fisher Exact- and unpaired Students t-test. 
For all statistical analyses, P-value <.05 was considered to be statistically significant.
RESultS
Patients
A total of 238 procedures, performed on 191 patients, were included to this study: 173 intra-
arterial thrombolytic procedures (70%: group I) and 65 thromboembolectomies (30%, group 
II) (Table 1). These procedures were performed on 145 men (61%) and 93 (39%) women with 
a mean age: 69±12.0 years. 
table 1. Basic characteristics.
Characteristics total 
(n = 238)
Group I (n = 173) Group II (n = 65) P-value
Gender 0.023*
Male 145 113 (65%) 32  (49 %)
Female 93 60  (35 %) 33  (51 %)
Age 0.19‡
Mean (±SD), years 69 (12.0) 68  (12.2) 70  (11.3)
ASA-classification§ 0.001*
Classification 1 24 16   (9.2 %) 8    (12 %) 0.49*
Classification 2 140 109 (63 %) 31  (48 %) 0.032*
Classification 3 58 43 (25%) 15  (23 %) 0.78*
Classification 4 16 5   (4 %) 11  (17 %) 0.000*
Comorbidity
Malignancy 18 7   (4 %) 11  (17 %) 0.001*
Abdominal aneurysm 9 6   (4 %) 3    (5 %) 0.71†
Arterial hypertension 108 80  (46 %) 28  (43 %) 0.66*
Diabetes 50 43  (25 %) 7    (11 %) 0.017*
History of smoking 148 107  (62 %) 41  (63 %) 0.86*
Cardiac disease 84 62  (36 %) 22  (34 %) 0.77*
Pulmonary disease 39 27  (16 %) 12  (18 %) 0.60*
Renal disease 58 39  (23 %) 19  (29 %) 0.28*
Carotid disease 31 21  (12 %) 10  (15 %) 0.51*
* = χ2-test; † Fisher’s Exact test; ‡ independent student-t test; § = American Society of Anaesthesiologists; Group I= 
intra-arterial thrombolysis; group II = thromboembolectomy.
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Risk factors and comorbidities 
Most procedures were performed on ASA-2 patients (n=140; 59%). In group I, significantly 
more procedures were performed in male patients and patients with diabetes (P<.05). 
Thromboembolectomies were significantly more performed in patients with ASA-
classification 4 or patients with active malignancies (P<.05). Age and all other comorbidities 
were not significantly different between both groups. 
table 2. Preoperative characteristics.
Characteristics total 
(n = 238)
Group I (n = 173) Group II (n = 65) P-value 
ALI-classification§
Class 1 2 2     (1.0%) 0     (0%) 1.00†
Class 2a 170 139 (80%) 31 (48%) 0.000*
Class 2b 64 31 (18%) 33 (51%) 0.000*
Class 3 2 1     (1 %) 1     (2 %) 0.47†
Days of complains 
Mean (±SD), years 5 (7.8) 6     (8.7) 3     (3.6) 0.001‡
Previous vascular surgery 118 97   (56%) 21    (32%) 0.001*
Location of occlusion
Bypass 109 90   (52%) 19    (29%) 0.002*
Femorofemoral crossover 3 2 1
Axillofemoral 6 1 5
Supragenicular 30 26 4
Infragenicular 35 30 5
Femorocrural 23 20 3
Aortobifemoral 8 7 1
EVAR 4 4 0
Aorto-iliac artery 29 19   (11%) 10    (15%) 0.36*
Common iliac artery 23 16 7
External iliac artery 7 4 3
Femoral arteries 52 26   (15%) 26    (40%) 0.000*
Common femoral artery 18 5 13
Superficial femoral artery 33 25 8
Femoral profunda artery 4 0 4
Popliteal artery 33 27   (16%) 6     (9%) 0.21*
Crural arteries 12 8     (5%) 4     (6%) 0.74†
* = χ2-test; † Fisher’s Exact test; ‡ independent student-t test; § = ALI-class = acute limb ischemia classification; Group 
I= intra-arterial thrombolysis; group II = thromboembolectomy.
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Procedure 
Significantly more procedures were performed on patients with marginal threatened ALI in 
group I (group I: 80% vs group II: 48%; P<0.05). Significantly more procedures were performed 
on patients with immediate threatened ALI in group II (group I: 18% vs group II: 51%; 
P<0.05). There were no differences in procedures performed on patients with viable ALI and 
irreversible ALI. There was a significant difference between both groups concerning the mean 
days of complains before intervention (group I: 6±8.7 vs group II: 3±3.6 days; P<.05) (Table 
2). In group I significantly more procedures were performed on patients with a past medical 
history of a vascular procedure (56% vs 32%; P<.05). Significantly more occluded bypass grafts 
were treated with thrombolysis compared to thromboembolectomies (52% vs 29%; P<.05) as 
listed in Table 2. A higher incidence of thromboembolectomies was registered in occluded 
femoral arteries. All other locations with occlusions were not significantly different between 
both groups. 
Outcome
One year primary patency rates were not significantly different between group I and group 
II (Figure 2). Thirty days - and 1 year patency rates in group I and II were 78% and 49% vs 59% 
and 43% (P=.144) respectively.
There were also no differences in thirty days - and 1 year limb salvage rates (Figure 3). Limb 
salvage rates in group I and II were 91% and 71% vs 79% and 66% (P=.166) respectively. 
After one year, significantly more patients were still alive after the procedure in group I (Figure 
4). Thirty days – and 1 year survival analyses in group I and II were 94% and 82% vs 88% and 
69% (P<.05) respectively.   
Adverse events 
A total of 195 AEs were registered in 131 procedures (55%). One-hundred and forty-nine 
(76%) of these AEs were procedure related. Haemorrhages were registered in 17 procedures 
(7%) and were equally divided between both groups. Surgical site infections were registered 
after 14 procedures (6%) and were also equally divided. Significantly more revascularisation 
failures occurred in group I (group I 28% vs group II 8%; P<.05). Significantly more arterial re-
occlusions occurred in group II (group I 9% vs group II 23 %; P<.05). (Table 3). 
Most AEs were procedure related (group I 77% vs group II 76%) and overall resulted in surgical 
reinterventions (group I 31% vs group II 49%). Overall irreversible physical damage were 
observed in 15% in group I and 25% in group II. Six percent of the total AEs resulted in death 
in group I and 12% of the AEs resulted in death in group II (Table 4).  
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 124 62 47 40 37
 0 0.046 0.047 0.048 0.048
 60 22 27 18 11
 0 0.069 0.065 0.071 0.075
figure 2. Kaplan-Meier curves representing primary patency rates of all successful intra-arterial thrombolysis (Group 
I) and thromboembolectomy (Group II) (log-rank, P = .144). SE, Standard error. 
figure 3. Kaplan-Me ier curves representing amputation-free survival of intra-arterial thrombolysis (Group I) and 
thromboembolectomy (Group II) (log-rank, P = .166). SE, Standard error.
 
 173 124 101 84 77
 0 0.028 0.034 0.036 0.038
 65 31 27 26 21
 0 0.062 0.065 0.067 0.067
Group I No. at Risk
SE
Group II No. at Risk
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Group I No. at Risk
SE
Group II No. at Risk
SE
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figure 4. Kaplan-Meier curves representing 1 year survival of intra-arterial thrombolysis (Group I) and 
thromboembolectomy (Group II) (log-rank, P = .020). SE, Standard error.
Group I: thrombolysis 
One hundred and forty-four AEs were registered after 93 procedures (Table 4). Most AEs were 
procedure related and reflected 77% of all AEs in group I. Thirty-nine per cent resulted in 
minor complications, 4% in additional medication or transfusion, 39% in reinterventions, 17% 
in irreversible physical damage and 1 % in early death. Infection related AE’s were registered in 
8 % of all AEs in group I. Seventy-five per cent resulted in additional medication or transfusion, 
17% resulted in early death and 8% in early death. Fifteen percent of all AEs in group I were 
organ related. Thirty-two per cent resulted in additional medication or transfusion, 27% in 
prolonged hospital stay, 5% in irreversible physical damage and 36% in early death.  
Group II: thromboembolectomies 
Fifty-one AEs occurred after 38 thromboembolectomies. Procedure related AEs reflected 76% 
of all AEs in group II. Ten per cent resulted in minor complications, 51% reinterventions, 31% 
in irreversible physical damage and 8% resulted in early death. Twenty per cent of all AEs in 
group II were infection related. Ten per cent resulted in additional medication or transfusion, 
50% in reinterventions, 10% in prolonged hospital stay, 10% in irreversible physical damage 
and 20% in early death. Four per cent of all AEs in group II were organ related. Fifty per cent 
resulted in additional medication or transfusion and 50% in early death (Table 4).
 
173 161 152 143 139
0 0.019 0.025 0.028 0.029
65 49 47 45 44
0 0.053 0.055 0.057 0.057
Group I No. at Risk
SE
Group II No. at Risk
SE
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table 3. Adverse Events registered after 131 procedures during admission or within 30 days after discharge.
Characteristics total 
(n = 238)
Group I (n = 173) Group II (n = 65) P-value
Procedure related
Revascularization failure 54 (23%) 49 (28%) 5 (8%) 0.001*
Re-occlusion 38 (16%) 15 (9%) 23 (35%) 0.000*
Compartment syndrome 12 (5%) 7 (4%) 5 (8%) 0.32†
Hemorrhages 17 (7%) 15 (9%) 2 (3%) 0.14*
Hematoma 24 (10%) 20 (12%) 4 (6%) 0.22*
Pseudo aneurysm 3 (1%) 3 (2%) - 0.56*
Seroma 1 (0%) 1 (1%) - 1.000†
Infection related
SSI 14 (6%) 6 (3%) 8 (12%) 0.47†
Pneumonia 6 (3%) 5 (3%) 1 (2%) 1.000†
Urinary tract infection 2 (1%) 1 (1%) 1 (2%) 0.47†
Organ related
Urinary retention 1 (0%) 1 (1%) - 1.000†
Acute renal failure 4 (2%) 4 (2%) - 0.58†
Myocardial infarction 2 (1%) 2 (1%) - 1.000†
Congestive heart failure 5 (2%) 4 (2%) 1 (2%) 1.000†
Arrhythmia 2 (1%) 2 (1%) - 1.000†
Ileus 1 (0%) 1 (1%) - 1.000†
Bowel ischemia 1 (0%) 1 (1%) - 1.000†
Anaphylaxis 2 (1%) 2 (1%) - 1.000†
Stroke 2 (1%) 2 (1%) - 1.000†
Delirium 4 (2%) 3 (2%) 1 (2%) 1.000†
* = χ2-test; † Fisher’s Exact test; ‡ independent student-t test; Group I= intra-arterial thrombolysis; group II = 
thromboembolectomy.
table 4. Adverse events (causes and consequences) after treatment for ALI of the total sample (n = 195).
Adverse events total Consequences
1A 1b 2A 2b 3 4
Group I Procedure related 110 (77) 43 (39) 4 (4) 43 (39) 0 (0) 19 (17) 1 (1)
Infection related 12 (8) 0 (0) 9 (75) 2 (17) 0 (0) 1 (8) 0 (0)
Organ related 22 (15) 0 (0) 7 (32) 0 (0) 6 (27) 1 (5) 8 (36)
Total AE’s 144 (100) 43 (30) 20 (14) 45 (31) 6 (4) 21 (15) 9 (6)
Group II Procedure related 39 (76) 4 (10) 0 (0) 20 (51) 0 (0) 12 (31) 3 (8)
Infection related 10 (20) 0 (0) 1 (10) 5 (50) 1 (10) 1 (10) 2 (20)
Organ related 2 (4) 0 (0) 1 (50) 0 (0) 0 (0) 0 (0) 1 (50)
Total EA’s 51 (100) 4 (8) 2 (4) 25 (49) 1 (2) 13 (25) 6 (12)
Data are presented as n and (%); ALI = acute limb ischemia; AE = adverse event; 1A = minor complications, no long-
term consequence; 1B = additional medication or transfusion; 2A = surgical reoperation; 2B = prolonged hospital stay; 
3 = irreversible physical damage; 4 = death; Group I= intra-arterial thrombolysis; group II = thromboembolectomy.
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dISCuSSIOn 
Results from this present study demonstrates no superiority of intra-arterial thrombolysis 
on patency or amputation rates after 1 year follow-up. There was a considerable amount of 
adverse events registered which mostly were procedure related. Surgical reinterventions were 
the most frequently observed consequence of both treatments (group 1: 31% and group II: 
49%). Irreversible physical damage was observed in 15% in group I and 25% in group II. Six 
percent of the AEs resulted in death in group I and 12% of the AEs resulted in death in group II. 
Procedures
Patency - and limb salvage rates were not significantly different between both procedures 
after 1 year, which was comparable to prospective randomised controlled trial in literature(5-9). 
We did observe a significantly higher mortality rate in the thromboembolectomy group. This 
observation could be explained by a potential selection bias in choosing the initial treatment 
for certain patients. In our clinic, we preferably use intra-arterial thrombolysis in patients with 
ALI and reserve thromboembolectomy for situations in which rapid invention is indicated or 
intra-arterial thrombolysis is contra-indicated because of a patient clinical condition(13, 14).
Adverse events
We registered more re-occlusions after thromboembolectomies. A possible explanation for 
this is that the passage of an inflated thromboembolectomy catheter through a vessel lumen 
can cause serious endothelial damage(20). The loss of endothelial cells can potentially lead to 
clod-formation in the acute phase as well (21). Long-term effects of this injury are not known. 
Although, endothelial damage could theoretically also occur after thrombolytic therapy by the 
inserted catheter, it is more likely that this will occur more often after thromboembolectomies 
(21). 
Major haemorrhages are frequently mentioned AEs after thrombolysis (11, 20, 22) and are 
also frequently registered in our study. Although the incidence of haemorrhages were slightly 
higher after thrombolysis, we did not observe a significant difference in this AE between both 
procedures. Also more post procedural strokes were registered after intra-arterial thrombolysis 
with no significant difference between both groups. The non-significant difference is probably 
a result of the small numbers in our study since two meta-analyses demonstrated a significant 
higher risk of haemorrhages and stroke after intra-arterial thrombolysis (8, 9). 
Although thrombolysis is a minimal invasive endovascular intervention, more systemic AEs 
(organ related AE’s) were registered in this group. These AEs result in extensive morbidity and 
mortality (12). 
Reducing AEs is a major topic in contemporary medicine since this is largely related to patient 
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quality of life and health care cost (12, 18). We observed a large percentage of surgical/procedural 
AEs (77% of all AEs after intra-arterial thrombolysis and 76% after thromboembolectomies) 
suggesting possibilities for improvement. This could be achieved by structured changes in 
perioperative management and surgical protocols, eventually resulting in reduced AEs(23).  
Additionally, many isolated pharmaco-mechanical thrombolysis systems have been 
developed to minimize severe systemic adverse events or major haemorrhages after intra-
arterial thrombolysis(24-34). Although these results are promising most reports about these 
new techniques are based on case reports or small clinical studies. Future large clinical studies 
should be performed to demonstrate the value of these techniques in reducing AEs. 
limitations
Our study has limitations because of its retrospective design, which should be considered 
when interpreting the results. Patients with more than 6 weeks of complaints or patients with 
combined procedures were excluded in this study to reduce the effect of other procedures 
on adverse events. Results could therefore not be interpreted on these patients samples. We 
acknowledge that our data is collected from one single hospital and although it is a large 
referral hospital with 5 vascular surgeons AE rates might differ in other centres. We also 
acknowledge the fact that all AE registration systems will have some sort of underestimation. 
Future prospective studies have to be performed to replicate our findings about AEs after 
contemporary treatment of ALI. Finally, it should be appreciated that our result were obtained 
in one, high volume hospital based on a large patient population with ALI. 
COnCluSIOn
Acute limb ischemia is a serious clinical condition with high change of morbidity and mortality. 
Both, intra-arterial thrombolysis and thromboembolectomies are adequate therapies but 
result in a wide variety of adverse events resulting in serious morbidity and even death.
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Appendix 1 
thrombolysis protocol Amphia hospital, (the netherlands, breda).
Procedural information: 
• Pre-procedural measures were Angiography or Magnetic Resonance Angiography (MRA).
• Most procedures were approached from the contralateral femoral artery using a 6 F 45 
cm Terumo® sheath.
• The entire occluded segment was passed using a Terumo® glidewire.
• A 4 F McNamara® catheter was introduced into the occluded segment.
• Angiographic control every 8 or 12 hours; depending on the extensiveness of the lesion .
• Depending of the underlying vascular lesion an endovascular procedure was performed 
after thrombolysis.
• Thrombolysis was stopped in case of hemorrhage or no technical success after 24-48 
hours or fibrinogen <2g/l.
• Post-procedural hemostasis was derived using 6Fr AngioSeal (St Jude Medical) or manual 
compression of the puncture site.
thrombolysis 
• A bolus of Urokinase® (250.000 IU) was administered into the occluded segment, followed 
by infusion of 100.000 IU/h. 
• Heparin was also administered at the start of the procedure (5000 IU), followed by infusion 
of 800-900 IU/h.
• APTT and fibrinogen were checked every 4 hours and APTT-time was set to 60 sec.
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AbStRACt
background: Surgical site infections (SSI’s) are associated with severe morbidity, mortality 
and increased health care costs in vascular surgery. 
Objective: To implement a bundle of care in vascular surgery and measure the effects on the 
overall and deep-SSI’s rates. 
design: Prospective, quasi-experimental, cohort study.
methods: A prospective surveillance for SSI’s after vascular surgery was performed in the 
Amphia hospital in Breda, from 2009 through 2011. A bundle developed by the Dutch hospital 
patient safety program (DHPSP) was introduced in 2009. The elements of the bundle were 
(1) perioperative normothermia, (2) hair removal before surgery, (3) the use of perioperative 
antibiotic prophylaxis and (4) discipline in the operating room. Bundle compliance was 
measured every 3 months in a random sample of surgical procedures and this was used for 
feedback.
Results: Bundle compliance improved significantly from an average of 10% in 2009 to 60% in 
2011. In total, 720 vascular procedures were performed during the study period and 75 (10.4%) 
SSI were observed. Deep SSI occurred in 25 (3.5%) patients. Patients with SSI’s (28,5±29.3 
vs 10.8±11.3, p<0.001) and deep-SSI’s (48.3±39.4 vs 11.4±11.8, p<0.001) had a significantly 
longer length of hospital stay after surgery than patients without an infection. A significantly 
higher mortality was observed in patients who developed a deep SSI (Adjusted OR: 2.96, 95% 
confidence interval 1.32-6.63). Multivariate analysis showed a significant and independent 
decrease of the SSI-rate over time that paralleled the introduction of the bundle. The SSI-rate 
was 51% lower in 2011 compared to 2009.
Conclusion: The implementation of the bundle was associated with improved compliance 
over time and a 51% reduction of the SSI-rate in vascular procedures. The bundle did not 
require expensive or potentially harmful interventions and is therefore an important tool to 
improve patient safety and reduce SSI’s in patients undergoing vascular surgery.
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IntROduCtIOn
The occurrence of surgical site infections (SSI’s) in surgery results in reduced quality of 
life, increased hospital length of stay, increased likelihood of mortality, higher change of 
readmissions and re-interventions (1). In vascular surgery deep infections lead to re-operations 
with a high morbidity and even mortality, especially in patients who received a prosthetic 
graft resulting in higher health care costs (2, 3). Therefore in 2007 a study was performed in 
the Netherlands to determine the amount of preventable mortality in Dutch hospitals (4). SSI’s 
were amount the leading causes and based on these findings the Dutch hospital patient safety 
program (DHPSP) was developed. The DHPSP disseminates knowledge to the Dutch hospitals, 
especially in preventive programs and networking opportunities. Since the start in 2009, they 
set up a goal to reduce these highly preventable complications by 50% at the end of 2012. 
The program included a bundle to prevent the development of SSI (http://www.vmszorg.
nl/10-Themas/POWI) and consisted of four process measures which should be implemented 
with a total compliance of at least 90%. To quantify the effect of the interventions on the 
outcome the SSI-rate was measured using validated methods in a national registry (http://
prezies.nl). The bundle elements were: (1) perioperative normothermia, (2) appropriate hair 
removal before surgery, (3) the use of perioperative antibiotic prophylaxis and (4) discipline 
in the operation room. The first three measurements are evidence-based and are included in 
the current national guidelines for the prevention of SSI (http://www.wip.nl/free_content/
Richtlijnen/100720powi%20def.pdf ). The effect of improved discipline is generally recognized 
as an important aspect but few studies have addressed it. This is mainly caused by the lack 
of reliable methods to measure discipline. The expert team for SSI-prevention of the DHPSP 
decided to use the number of door openings during surgical procedures as a surrogate 
marker for discipline. 
The objective of this study was to implement the bundle of care in vascular surgery and 
evaluate the effects on the overall SSI-rate as well as the deep SSI-rate while adjusting for 
confounders.
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mEthOdS 
A prospective surveillance study for SSI’s based on the criteria of the Centers for Disease Control 
(5) was performed in the Amphia hospital in Breda. This is a large teaching hospital located 
in the south of the Netherlands with 45.000 clinical admissions in 2011 and five consultant 
vascular surgeons. The hospital’s infection control committee and the board of directors as 
part of the patient safety program approved this study. Also the medical ethical committee of 
the Amphia Hospital in Breda, the Netherlands, permitted this project and waived informed 
consent.
Patients with a peripheral or central vascular reconstruction between March 2009 and January 
2012 were included for analysis. The following characteristics were recorded: age, gender, 
ASA-score, length, weight, body mass index, wound class, type of procedure, central versus 
peripheral procedure, elective versus urgent, temperature at the end of surgery, duration 
of surgery, surgeon, number of vascular procedures per surgeon during the study period, 
admission date, date of surgery, discharge date, readmission within the post-discharge 
period, development of a SSI, development of a deep SSI and mortality within 6 months after 
the initial procedure. 
Registration of SSI`s was performed by dedicated and specifically trained infection control 
personnel routinely performed the surveillance. Post-discharge surveillance was performed 
on all patients until 6 months after the date of the procedure.
The definition for SSI’s and deep-SSI’s, as described elsewhere, was based on the criteria of the 
Centers for Disease Control (5). 
In 2009 the bundle to reduce SSI’s as defined by the DHPSP was implemented in our hospital. 
Starting in June 2009 bundle adherence was measured every three months using a random 
sample of 10 procedures. Normothermia was defined as a core temperature between 36.0ºC 
and 38.0ºC at the end of the surgical procedure. Perioperative prophylaxis was considered 
correct when the indicated antibiotic (according to the hospital formulary) was given 
between 15 and 60 minutes before the incision. Hair removal was preferably not performed 
and when it was done a clipper had to be used. Use of a razor blade was not allowed. Finally, 
the number of door-openings was measured from opening of the sterile equipment until 
the surgical wound was closed. This was done by visual inspection performed by infection 
control personnel. The target for door-openings was <10 per hour. Besides the amount of 
door-openings the reason for entering the operation room was also recorded. Eventually 
these data were used for feedback and development of strategies for improvement.
The development of the introduction of the bundle was evaluated after each measurement 
in a multidisciplinary team consisting of surgeons, anesthetists, the head of the operating 
room, operating room personnel and infection control personnel. Every three months the 
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results of the adherence to the bundle was communicated to all personnel involved in 
the surgical process. They received a newsletter that informed them about the results of 
the bundle compliance and recommendations for improvement. The management of the 
hospital supported the program (which included more surgical specialties than vascular 
surgery) by the allocation of one full time equivalent infection control nurse to the program 
for surveillance of SSI, bundle measurements and feedback.
The following interventions for improvement were performed: 
1. Hair removal was performed by a clipper instead of a razorblade
2. Timing and the use of pre-operative antibiotics were agreed upon by all participants 
and written in a protocol that could be handled by anesthesia personnel without 
consulting the surgeon. Before the operation started a time-out procedure was in 
place, which included the administration of antibiotic prophylaxis. 
3. Temperature of the patient was measured during the entire process from the ward 
to the operating theatre and back to the ward. Based on the findings an isolation 
blanket was administered to patients on the ward before they were transported to 
the operating room. Previously this blanket had been administered in the operating 
theatre.
4. Door openings were subjected to a root-cause analysis. The multidisciplinary 
team critically assessed the determinants of openings and recommendations 
for improvement were made. The management of the OR was responsible for 
implementation of these recommendations. The main interventions were: reducing 
changes of the team for coffee breaks, making sure all equipment was present before 
the surgical procedure started and not entering the operating room for social talks 
during the surgical procedure. 
5. For the implementation of the bundle a safety culture was promoted, in which personal 
feedback was done when the bundle adherence was at risk. 
6. After each bundle measurement a newsletter as described before was provided as 
feedback about the progress of the introduction of the bundle. 
Statistical analysis 
All variables were univariate tested as appropriate by Fishers exact test or Students T-test. 
Variables with P <0.2 in univariate analysis were included in a multivariable logistic regression 
model. P <0.05 was considered statistically significant. Mortality was compared using Kaplan 
Meier survival analysis. A Cox-regression analysis was performed to adjust for confounders. 
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RESultS
Figure 1 shows that the compliance of the bundle per annual quarter started at 10% and 
improved to 80% by the end of 2011. At the start, the individual bundle elements had a 
variable compliance. Correct prophylactic antibiotic use was already high from the start of 
the program. Door movements were the most resilient topic for improvement (Figure 2). The 
annual compliance with the bundle elements increased gradually and statistically significant 
from 10% in 2009 to 60% in 2011 (Fig 2, p<0.05). 
table 1. Categorical variables in relation to the occurrence of surgical site infections (SSI) after vascular surgery.
determinant deep
SSI/n
% RR 95% CI p-value
Gender Male 54/538 10.0
Female 21/182 11.5 1.17 0.69-2.00 0.576
Procedure Central 23/368 6.2
Peripheral 52/352 14.8 2.36 1.48-3.78 <0.001
Number of procedures per 
surgeon during study
1-100 27/229 11.8
>100 48/491 9.8 0.83 0.53-1.30 0.433
ASA class 1 or 2* 18/179 10.1
3,4 of 5 57/532 10.7 1.07 0.61-1.88 0.889
Wound score 1 73/700 10.4
≥2 2/20 10.0 0.95 0.22-4.20 1.000
Urgency of procedure Elective 71/642 11.1
Non-elective 4/77 5.2 0.44 0.16-1.24 0.164
Death within 6 months Yes 11/69 15.9
No 64/651 9.8 0.62 0.342-1.11 0.143
Year 2009 27/181 14.9
2010 27/290 9.3 0.62 0.35-1.10 0.074
2011 21/249 8.4 0.57 0.31-1.03 0.043
ASA class: American Society of Anesthesiologists classification; Wound class: Classification based on the intrinsic 
contamination of the incision site; * ASA 1: 3 pts, ASA 2: 176 pts.
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figure 1. Compliance with the bundle and its individual components in repeated measurements from June 2009 
through October 2011.
figure 2. Annual changes in the surgical site infection (SSI) rate and bundle compliance and the 95% confidence 
interval.
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Surgical site infections 
In a total of 720 vascular procedures 75 (10.4%) SSI’s were documented. The SSI-rate was 
significantly higher in peripheral versus central procedures (table 1). The SSI-rate declined 
significantly over time. Compared with 2009, the SSI-rate was 44% lower in 2011. Continuous 
variables in relation to the occurrence of SSI demonstrated that patients who developed a SSI 
had a significantly longer duration of the surgical procedure (Table 2).
table 2. Continuous variables in relation to the occurrence of surgical site infections (SSI) after vascular surgery.
With SSI Without SSI
mean Sd mean Sd p-value
Age in years 68.9 11.5 70.8 9.8 0.129
Duration of surgery in minutes 168.0 74.5 146.4 65.6 0.008
Body mass index in kg/m2 26.1 5.0 25.6 4.0 0.367
Length of hospital stay after surgery 28.5 29.3 10.8 11.3 <0.001
A significant reduction of the SSI rate was observed in 2010 and 2011, with a 51% reduction in 
the last year of the study, compared to 2009. The increased compliance with the bundle was 
therefore associated with a decrease of the SSI-rate (Fig. 2). 
deep surgical site infections
In a total of 720 vascular procedures 25 (3.5%) deep-SSI’s were documented. This occurred 
significantly more in peripheral versus central procedures and the incidence in 2011 compared 
to the start of the study in 2009 was 44% lower (table 3 and 4).  
To adjust for confounding a logistic regression analysis was performed as shown in table 5. 
With the exception of gender, age and elective versus non-elective procedures most variables 
that were identified in the univariate analysis retained their statistical significance. 
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table 3. Categorical variables in relation to the occurrence of deep surgical site infections (deep SSI) after vascular 
surgery.
determinant deep
SSI/n
% RR 95% CI p-value
Gender Male 17/538 3.2
Female 8/182 4.4 1.41 0.60-3.32 0.482
Peripheral 5/368 1.4
Procedure Central 20/352 5.7 4.18 1.59-11.02 <0.001
Number of procedures per 
surgeon during study
1-100 12/229 5.2
>100 13/491 2.6 0.51 0.23-1.09 0.084
ASA class 1 or 2* 7/179 3.9
3,4 of 5 18/532 3.4 0.86 0.35-2.10 0.815
Wound score 1 23/700 3.3
≥2 2/20 10.0 3.27 0.72-14.94 0.150
Urgency of procedure Elective 23/642 3.6
Non-elective 2/77 2.6 0.72 0.17-3.11 1.000
Death within 6 months Yes 7/69 10.1
No 18/651 2.8 0.27 0.12-0.63 0.006
Year 2009 9/181 5.0
2010 9/290 3.1 0.62 0.24-1.60 0.33
2011 7/249 2.8 0.57 0.21-1.55 0.27
ASA class: American Society of Anesthesiologists classification; Wound class: Classification based on the intrinsic 
contamination of the incision site; * ASA 1: 3 pts, ASA 2: 176 pts.
table 4. Continuous variables in relation to the occurrence of deep surgical site infections (deep SSI) after vascular 
surgery.
With SSI Without SSI
mean Sd mean Sd p-value
Age in years 72.0 10.9 70.5 9.9 0.472
Duration of surgery in minutes 150.9 53.1 148.6 67.3 0.861
Body mass index in kg/m2 25.5 4.9 25.7 4.1 0.764
Length of hospital stay after surgery 48.3 39.4 11.4 11.8 <0.001
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Outcome in patients after surgical site infections
Patients who developed a SSI had a longer post-operative length of stay in the hospital (mean 
additional length of stay: 18 days (Table 2). In patients who developed deep SSI the post-
operative length of stay was even longer (mean additional length of stay: 37 days (Table 4). 
No statistical significant difference was seen in the Kaplan Meier curve for 6 months mortality 
of patients with and without a SSI (P:0.126 using the Log rank test). However, there was a 
significant difference in 6 months mortality of patients with and without deep SSI (P<0.001 
(fig 3)). Cox-regression analysis demonstrated a statistical significant difference for mortality 
between patients with and without deep SSI’s adjusted for ASA score and age (adjusted OR: 
2.96, 95% confidence interval 1.32-6.6).
table 5. Multivariate analysis of variables in relation to the occurrence of surgical site infections (SSI) after vascular 
surgery with adjusted Odds ratio’s (AOR) and the 95% confidence interval (CI).
Variable AOR 95% CI p-value
Gender 1.09 0.63-1.91 0.753
Central versus peripheral procedure 0.40 0.23-0.68 0.001
Elective versus acute procedures 0.45 0.23-1.92 0.447
Duration of surgery (10 minutes) 1.04 1.00-1.00 0,022
age (years) 0.98 0.96-1.00 0.106
year (2010 versus 2009) 0.53 0.29-0.95 0.032
year (2011 versus 2009) 0.49 0.26-0.91 0.024
dISCuSSIOn
Our results confirm that SSI’s are relatively frequent (10.4%) and severe complications among 
patients who undergo vascular surgery. In this study, patients who developed a SSI had a 
prolonged hospital stay (18 days), which was even more pronounced when deep SSI occurred: 
mean length of hospital stay (37 days) and in these patients there was also a significantly 
higher mortality rate. This stresses the importance in preventing surgical site infections. 
The introduction of the bundle as defined by the DHPSP was associated with a strong and 
significant reduction of the SSI-rate in patients after vascular surgery. Due to the design 
of the study we cannot entirely be sure that there have been other unknown factors that 
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contributed to the reduction of the SSI-rate. As we adjusted for confounders we consider it 
very likely that the reduction of the SSI-rate was largely due to the introduction of the bundle. 
The bundle exists of four components, which are scientifically proven and do not require 
expensive or complicated interventions. For vascular surgery, a 50% reduction would mean 
that approximately 18 SSI are prevented per year in our institute. Based on the additional 
length of stay of 18 days this would potentially save over 300 days of hospital stay per year. 
The mean costs a day in our hospital are estimated to be approximately €500, meaning 
that the total savings would be close to €150,000. Since the bundle elements are cheap it is 
likely that this is a highly cost-effective intervention. Our maximum bundle compliance per 
measurement was 80%. This is less than the 90% that was defined as a target at the onset of 
the program. Therefore, additional improvements are possible and may even further reduce 
the SSI-rate. We have continued the program and by the end of 2012 the compliance was 
90%. As the SSI-rate can only be determined after a follow up of half a year the effects on the 
SSI-rate cannot be determined at this moment.
The importance of a bundle of care to reduce hospital infections have become clear since a 
large multicenter study was performed in the United States of America to reduce catheter-
related-infections and in a later study the reduction of ventilator-associated pneumonia in 
 
figure 3. Kaplan-meier curve of 6 months survival in patients with and without a deep surgical site infection (deep 
SSI).
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the ICU (6, 7). A few studies have described the effects of a bundle of measurements on the 
prevention of SSI’s after colorectal surgery. One study in colorectal surgery demonstrated a 
positive trend but had a small sample size so no definite conclusions could be drawn (8). 
Another randomized study had a disappointing result, as the SSI-rate in the group with the 
bundle was increased (9). The main criticism on this study is that the bundle used, was mainly 
based on technical adjustments and did not encourage a structural improvement in the 
overall surgical process to create a safety culture.
The bundle that we used has already been described before (10). It was studied in the same 
time period in our hospital for the prevention of SSI’s after colorectal surgery (11). Also 
after colorectal surgery a substantial (36%) and significant reduction of the SSI-rate was 
observed after implementation of the bundle. We observed an even stronger effect of the 
implementation of the bundle on the reduction of SSI’s in vascular surgery. Another study 
published in august 2012 also described a reduction of SSI’s in patients having colorectal 
surgery after the implementation of a comparable bundle of care. The following bundle of 
six measurements was introduced: standardization of skin preparation; administration of 
preoperative chlorhexidine showers; selective elimination of mechanical bowel preparation; 
warming of patients in the preanesthesia area; adoption of enhanced sterile techniques for 
skin and fascial closure; addressing previously unrecognized lapses in antibiotic prophylaxis 
(12). After implementation, they observed a 33.3% reduction of SSI’s, which was comparable 
to the results with colorectal surgery in our institute. Due to their SSI’s reduction they also 
concluded that the implementation of the bundle resulted in major annual cost savings in 
their institution. This assumption is not entirely valid since it cannot be assumed that patients 
with SSI’s or deep SSI’s will not be suffering from other underlying reasons that cause their 
longer length of hospital stay. However it is likely that reducing SSI’s is associated with lower 
annual cost.     
In our study, the wound care and compliance with hand hygiene during the postoperative 
phase could also contribute to the development of SSI’s and this was not included in the 
intervention. However, since we adhered to the national guidelines on wound care (www.
wip.nl) and only included primary closed wounds which are less prone to post-operative 
contamination and did not require special postoperative wound care we assume no 
important contributory effect of wound care on the development of SSI’s. The effects of hand 
hygiene compliance on the wards could have had a negative effect on the development of 
SSI’s and should not be underestimated. In this study, we did not analyze the hand hygiene 
compliance. A contributory effect can therefore not be excluded.
The longer length of hospital stay in patients with SSI’s is, as mentioned before, not necessarily 
caused by the SSI’s but may in part be due to other underlying factors. This study cannot 
define the contribution of SSI’s to the observed increase in the length of hospital stay. 
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However, others have shown that SSI’s cause a substantial length of hospital stay and a double 
blind randomized study using a preventive intervention showed that prevention of SSI’s is 
associated with substantial cost savings (13). Therefore, we conclude that SSI’s will have an 
important effect on the length of hospital stay but the exact amount cannot be determined 
in this study. 
There are some other limitations to be mentioned to this study. First we could not demonstrate 
a direct causal relationship between the implementation of the bundle and the reduction of 
SSI since we did not use a randomized controlled study design. This study design is not feasible, 
when a change in behavior is part of the intervention. Health care workers cannot change 
their behavior based on individual randomization. Second, the year before the introduction 
of the bundle, our hospital was participating in the SURPASS study (14) that introduced the 
time-out procedure and the preoperative checklist. Since this study finished one year before 
we started this study, we cannot exclude a residual effect of this study on our results. Third, we 
did not perform an interrupted time series analysis since the interventions were implemented 
over a longer period of time (1 year and through the entire study period). Finally, we cannot 
exclude the positive effects of the routine feedback moments and discussions causing 
unknown behaviour effects on SSI reduction. They may have contributed to the reduction of 
SSI-rate as well. 
In vascular surgery SSI’s have been reported to occur in 5-10% of patients (central and 
peripheral procedures) and could become life-threatening especially when prosthetic grafts 
are involved. This makes SSI-reduction an important topic for improvement. Mostly technical 
preventative measurements have been described to reduce vascular SSI’s. There are also 
studies suggesting the importance of maintaining peri-operative physiological parameters 
(oxygen, temperature, blood sugar and intravascular volumes) (2, 3). To our knowledge 
none of these evidence based inventions has been bundled and structurally implemented 
to reduce surgical site infections in vascular surgery. To reduce these SSI’s, we implemented 
a bundle of measurements introduced by the DHPSP. Others and we demonstrated that 
the strict implementation of the bundle results in a substantial and significant reduction 
of the infection rate and therefore improves the safety for surgical patients having vascular 
procedures. As the bundle did not involve expensive or potentially harmful elements we 
recommend the implementation of this bundle on a large scale. 
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AbStRACt
background: Patients with peripheral arterial disease (PAD) are at risk for revision surgery in 
the groin and therefore at potential risk for surgical site infections (SSIs). In an observational 
study, a cohort of patients with peripheral arterial disease was followed to examine the effect 
of different incision intervals on SSI-free survival.
methods: Patients, needing peripheral vascular surgery because of PAD, were retrieved from 
a prospectively collected database on SSIs after vascular surgery between March 2009 and 
January 2012, the group consisting of 720 patients. Of these, 255 patients were selected (age 
71.9 – 10.4 y). Cox proportional hazards models were used for event-history analyses. The effect 
of incision interval was estimated with adjustment for a number of potential confounders. 
Effects were quantified by means of hazard ratios (HRs) with 95% confidence intervals (CIs).
Results: No significant effect on the incision interval on SSI-free survival was observed. After 
separating incisional SSIs into superficial- and deep-seated, a significant linear trend effect of 
the groin incision interval on deep-incisional SSI development was observed: the shorter the 
interval, the higher the event rate (HR 1.5 per category, 95% CI 1.1–2.1, p = 0.22). Besides the 
incision interval, the Rutherford classification was a significant risk factor for SSI development 
(HR 3.0; 95% CI 2.1–4.2; p < 0.0005).
Conclusion: Revision surgery in the groin puts patients at risk for deep-incisional SSI. No effect 
on superficial incisional SSI development was observed. Besides the incision interval, the 
Rutherford classification was a significant risk factor for both superficial- and deep-incisional 
SSI. Quality improvement and better risk stratification schemes are suggested.
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IntROduCtIOn 
Severe peripheral arterial disease (PAD) is associated with major complications after vascular 
surgery, as well as higher cardiovascular event rate, comorbidities, and death (1, 2) Given this 
information, better outcome predictions for this particular group are needed to improve 
treatment strategies.
A common complication after vascular surgery is a surgical site infection (SSI) (3), which 
is associated with increased hospital length of stay (LOS), morbidity, readmissions, re-
interventions, and death (4). Deep-incisional SSI could, with the use of prosthetic grafts, lead 
to high morbidity and mortality rates. Reduction of the incidence of these SSIs therefore is 
necessary.
A groin incision for femoral artery access is a risk factor for these SSIs (5, 6). Additionally, in an 
aging population wherein risk factors for the development of severe PAD increase, a higher 
demand for peripheral surgical revascularization and re-intervention is expected (4, 7, 8). 
Multiple groin incisions could lead to a high incidence of complications; e.g., SSI. 
To our knowledge, there is little information on the effect of different groin incision intervals on 
patient outcomes such as SSI. This lack of knowledge could have serious clinical consequences.
The present study was performed to evaluate the effect of different groin incision intervals 
after elective vascular procedures on patients with moderate to severe PAD with regard to SSI 
development. Previously, groin incisions, performed at different times, were analyzed for their 
influence on SSI-free survival. 
mEthOdS 
data collection and study population
A prospectively collected database on surgical site infections (SSI) after 720 central and 
peripheral vascular procedures performed between March 2009 and January 2012 (3) was 
studied to retrieve all patients with PAD seen in the Amphia Hospital. For this database, the 
hospital’s infection control committee and the board of directors as part of the patient safety 
program and the medical ethical committee approved this study and waived informed 
consent. 
All patients were selected on the basis of operation codes corresponding to endarterectomy 
of the femoral artery and peripheral bypass surgery. Patients undergoing popliteal aneurysm 
repair, endovascular procedures of the lower and upper extremities, central vascular 
procedures, or endarterectomy of the carotid artery were excluded from this study. 
Procedures were performed in an institution with five vascular surgeons. All patients were 
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worked up via duplex ultrasound examination and magnetic resonance angiography. 
Endartectomies were performed according to standard vascular procedures. Whenever 
possible, autologous grafting was performed in peripheral bypass surgery. Alternatively, an 
expanded polytetrafluoroethylene (ePTFE) pre-cuffed Dynaflo® graft (Bard Peripheral Vascular 
Inc., Tempe, AZ USA) was used for supragenicular femoropopliteal bypass reconstructions and 
the Distaflo® (Bard Peripheral Vascular) for infragenicular femoropopliteal and femoralcrural 
bypass reconstructions (9). 
Surgical site infections (SSI), defined according to the criteria of the Centers of Disease Control(10), 
were monitored prospectively. A distinction was made between superficial and deep-incisional 
SSI’s. Registration of SSIs was performed by dedicated and trained infection control personnel. 
The presence of a SSI was ascertained by a microbiologist and a vascular surgeon (3). 
Previous procedures were recorded (before and at inclusion) and procedures during the 
follow-up period in which the groin was involved. A previous groin procedure was defined as 
a procedure at the groin to improve vascular circulation (patch, bypass, or thrombectomy) or 
to stop major bleeding, there being no indication of an infection. Drainage from abscesses, 
seromas, hematomas, or wound debridement was not included in the analyses as a previous 
groin incision. Also, percutaneous transluminal angioplasty (PTA) and thrombolysis were not 
included in the groin procedures.
Other data, aside from SSI’s and procedures, collected from patient records were age, gender, 
the American Society of Anaesthesiologists (ASA)-score, height, weight, and body mass index 
(BMI); presence of diabetes mellitus, chronic obstructive pulmonary disease (COPD), or chronic 
kidney disease; Rutherford classification; the use of synthetic grafts (bovine patches or ePTFE 
bypasses); amputation; and death.
Outcome measures: 
The outcome variable to be analyzed was SSI-free survival time. The endpoint was either an 
SSI or death while SSI-free. Also, a distinction was made between superficial and deep-SSI. 
Censoring of the follow-up was at the predetermined 90th day after the inclusion operation 
and could therefore properly assumed to be non-informative for the incidence time of the 
endpoint as defined.
follow-up:
Surveillance was performed in a time period in which the patient was considered most prone 
to infections. All patients were followed until 90 days after the date of the initial procedure 
(during admission and on the outpatient clinic) or till the day of death when earlier than 90 
days. 
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Statistical analysis: 
The purpose of the statistical analyses was to estimate the effects of a number of independent 
variables on SSI-free survival time using event-history analysis. Primary interest was in the 
effect of previous groin procedures on SSI-free survival time. Of interest was the interval 
between two consecutive incisions. This interval was defined as the time between the two 
last incisions prior to the occurrence of an event and so was accounted for in the analysis 
as a time-dependent covariable. The following categorization for the groin incision-interval 
between the last-but-one incision and the last incision was used: less than 2 weeks, between 
2 weeks and 6 months and more than 6 months, versus no previous groin operation.
The Cox proportional hazards model was used for the event-history analyses. Firstly an 
unadjusted effect of the incision-interval as defined above was estimated. In more elaborate 
analyses the effect of the incision-interval was estimated with adjustment for a number of 
potentially confounding variables. Along with incision-interval, age (in years) was entered in the 
model being an important risk factor in elderly patients. Occurrence of an amputation during 
follow-up was considered a confounding covariable to be adjusted for when considering the 
effect of incision-interval on SSI-free survival time. So, amputation (y/n) was entered in the 
model as a time-dependent covariable. Entry of other explanatory variables in the model was 
based on a backward elimination procedure so as to delete variables from the model with a 
p-value above 0.20 in a stepwise manner. Those candidate other variables were mentioned 
above. The synthetic graft variable was based on the last operation before the occurrence 
of an event and thus was entered in the model as a time-dependent covariable. Effects of 
the independent variables on the various survival times were quantified by means of hazard 
ratios (HR) with 95% confidence intervals (CI) and p-values. Logistic regression analysis was 
performed among the patients with an SSI in order to investigate which variables were able to 
discriminate between deep seated and superficial SSI’s. Those discriminating variables should 
have an effect on the occurrence rate of a deep SSI that differs from that on the occurrence 
rate of a superficial SSI.
Statistical analyses were done using the SPSS® software program version 20 (IBM, Armonk, 
New York, USA). P-values below 0·05 were considered to denote statistical significance. 
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RESultS
This study included 255 consecutive patients who had a surgical revascularization because of 
PAD (Rutherford class 3-6) in our hospital. The mean age for all patients was 71.9±10.4 years, 
173 (68%) were male. At the time of inclusion, 184 (72.2%) underwent a primary procedure 
and were not involved in a previous groin incision, none had a groin incision less than 2 weeks 
ago, 8 (3.1%) had an incision between 2 weeks and 6 months ago and 63 (24.7%) had an 
incision more than 6 months ago. These numbers were updated during follow-up after each 
operation. After 90 days of follow-up 236 patients were still alive, 160 (67.8%) did not undergo 
another operation, 15 (6.4%) had a groin incision less than 2 weeks ago, 12 (5.1%) had an 
incision between 2 weeks and 6 months ago and 49 (20.8%) had an groin incision more than 6 
table 1. Baseline characteristics of study population (n= 255).
Characteristic
Mean age in years (± SD) 71.9 ± 10.4
Male/Female 173 (68)/82(32)
ASA-classification*
I or II 54 (21.2)
III, IV orV 200 (78.4)
Mean BMI (± SD) 25.3 ±3.6
Comorbidity
COPD 50 (19.6)
Chronic kidney disease 30 (11.8)
Diabetes 86 (33.7)
Rutherford classification
3 97 (38)
4 70 (27.5)
5/6 88 (34.5)
Total procedures performed 292
Primary procedure at inclusion 184 (72.2)
Procedures at inclusion
Endarterectomy, CFA 97 (38)
Supragenicular bypass (%) 61 (23.9)
Infragenicular bypass (%) 48 (18.8)
Femorocrural bypass (%) 49 (19.2)
Data are presented as n and (%), unless otherwise specified, ASA American Society of Anesthesiologists score, BMI 
body mass index, COPD chronic obstructive pulmonary disease, CFA common femoral artery.
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months ago. The 255 patients contributed 292 operations, of which in 173 operations (59.2%) 
synthetic grafts were used. Other basic patient characteristics are listed in table 1.
The 255 operated patients contributed in total 21,863 person-days alive after operation. 
During follow-up 19 patients (7.5%) died and 38 patients (14.9%) developed an SSI (s. aureus 
cultured in 45%). Of these 38 patients, 15 patients (5.9%) turned out to have a deep-SSI. 
SSI-free survival 
During follow-up, the following events were registered in 51 patients: 38 patients developed 
an SSI and 13 patients died while SSI-free. The unadjusted overall effect of the incision-interval 
on event-free survival was not significant (p = 0.38). In the subgroup with an incision-interval 
less than two weeks a non-significantly higher event rate was seen compared to the subgroup 
with no former incision (HR = 2.09; 95% CI: 0.87-5.02; p = 0.10).
After adjusting for potential confounders, no significant effect of the groin incision-interval 
on SSI-free survival was observed either (p = 0.97); see Table 2. An incision-interval less than 
2 weeks resulted in a 1.2 times higher event rate than in case of no previous groin incision, 
although this was also not significant. The Rutherford classification (HR = 3.0 per 1 point 
higher) had a significant effect on SSI-free survival. During follow-up 14 patients underwent 
a major amputation while SSI-free. After an amputation the event rate was not significantly 
higher (HR = 1.4; p = 0.56) than that of patients who had no amputation at that time. Also the 
effect of age (a 2 % event increase per year) was not significant (p = 0.36). Each of the variables 
that were backwards eliminated from the model (gender, diabetes, synthetic graft, COPD, 
renal impairment, ASA-score or BMI) did not have a significant effect on SSI-free survival when 
added to the final model presented in Table 2 (p-values ranging from 0.5 to 0.9; data not 
shown).
table 2. Results of Cox proportional hazards regression analysis on SSI-free survival based on 51 events in 255 patients.
Explanatory variable Coefficient hazard ratio (95 % CI) P-value
Interval between two last groin incisions 0.97
None 0 1
< 2 weeks 0.192 1.21 (0.42-3.48)
2 weeks - 6 months -0.255 0.78 (0.18-3.29)
> 6 months -0.015 0.99 (0.51-1.92)
Rutherford-classification (+ 1 point) 1.101 3.01 (2.15-4.20) < 0.0005
Age (+ 1 year) 0.015 1.02 (0.98-1.05) 0.36
Amputation (time-dependent) 0.307 1.36 (0.48-3.84) 0.56
Model test: χ2- = 68.860 (df = 6); p < 0.0005.
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Deep-SSI
In 15 of the 38 patients with an SSI the SSI turned out to be a deep seated SSI. The variables 
that significantly differed between patients with a deep-SSI and those with a superficial SSI 
were: last incision-interval before the SSI (the shorter the interval, the larger the probability 
that the SSI was deep), Rutherford classification (effect in favor of a deep seated SSI) and 
BMI (effect in favor of a superficial SSI). In these analyses incision-interval as linear trend 
variable (with no previous incision defined as the highest category) gave a better fit than 
incision interval as categorical nominal variable. After having entered these three variables 
simultaneously in a logistic regression model, the Rutherford classification lost its significance 
(p = 0.41). The variables incision-interval and BMI kept their effects in the directions as just 
mentioned (both p-values 0.003). In order to further investigate the effects of these variables 
on SSI-free survival while distinguishing between deep and superficial SSI’s we entered these 
variables simultaneously in two Cox proportional hazards regression analyses: one for deep-
SSI with 29 events (15 SSI’s and 14 deaths) and the other one for superficial SSI with 41 events 
(23 SSI’s and 18 deaths). Incision-interval appeared to have a significant linear trend effect on 
deep-SSI-free survival: one category shorter incision-interval was associated with an HR of 
1.5 (95% CI: 1.1-2.1; p = 0.022). A non-significant reverse linear trend effect of incision-interval 
was seen on superficial SSI-free survival: HR = 0.75 per category shorter incision-interval (p 
= 0.19). The Rutherford classification had large positive significant effects on the event rates 
concerning deep- as well as superficial SSI-free survival with respective HR’s of 6.7 and 3.0 
per point higher on the scale (p-values < 0.0005). BMI appeared to have a significant reverse 
effect on the event rate concerning deep-SSI-free survival: HR = 0.89 per 1 unit kg/m2 (95% 
CI: 0.81-0.99; p = 0.025). A non-significant positive effect of BMI was found on the event rate 
concerning superficial SSI-free survival: HR = 1.06 per 1 unit kg/m2 (95% CI: 0.98-1.14; p = 0.15). 
The extent to which these results on SSI-free survival differed between deep and superficial 
SSI-free survival was in line with the above mentioned results of the logistic regression analysis 
on the 36 SSI’s, as it should. 
dISCuSSIOn
The results from the present study demonstrate that the frequency of repeated vascular 
revision surgery at the groin is not a risk factor for SSI development. Only after separating SSIs 
into superficial and deep-seated, a significant linear trend effect of the groin incision interval 
on deep-SSI development was observed: the shorter the interval, the higher the event rate. 
This suggests early revision surgery in the groin to be a risk factor for deep-SSI development. 
The incision interval had no significant effect on superficialincisional SSI development. Besides 
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the incision interval, the Rutherford classification is a significant risk factor for superficial as 
well as deep-seated incisional SSI development. This effect did not differ significantly between 
superficial and deep-seated-incisional SSIs.
Each shorter incision interval was associated with an increased risk of deep-incisional SSI 
development (1.5 per category). Kolakowski et al. reported early revision of lower extremity 
bypass grafts (within one month), compared with late revision (after one month) to be a risk 
factor for graft infection (11) and stated reintervention should be delayed until one month 
after initial surgery. Unfortunately, in most cases, revision surgery cannot be delayed because 
of severe, even critical, limb ischemia (12). Alternative procedures for vascular revision could 
therefore be considered. For example, extra-anatomic surgical approaches and percutaneous 
transluminal interventions might be performed to resolve stenosis or occlusions (13), but 
current literature on these interventions performed in this situation is lacking. 
The Rutherford classification turned out to be a strong risk factor for SSI development. We 
could not demonstrate that the effect of the Rutherford classification on deep-incisional SSI 
development differed from that on superficial-incisional SSI development (p = 0.41 adjusted 
for incision interval). The poor peripheral and subcutaneous vascularization status in which 
wound healing might be impaired and micro-organisms have a better chance of growth 
could be an explanation.
The BMI was a non-significant risk factor for superficialincisional SSI development in this study 
and had a significant protective effect on deep-incisional SSI development. This effect of BMI 
differed significantly between superficial and deep-seated incisional SSIs. In the literature, BMI 
is associated with SSI development (14, 15), but no distinction was made between superficial 
and deep-incisional SSIs in these studies. A potential explanation is that in the case of a high 
BMI, prosthetic grafts are better embedded in subcutaneous tissue.
A synthetic graft infection is a well-known risk factor for amputation (15). A logical explanation 
for this could be the fact that, at the time of presentation, no reconstructive options are 
available if a limb is not salvageable because of critical limb ischemia. Besides this, SSIs are also 
is associated with higher morbidity and mortality rates (4). The reduction of SSI is therefore 
highly desirable. In our hospital, several interventions have been undertaken to reduce SSIs, 
namely the introduction of the Surgical Patient Safety System (SURPASS) checklist (16) and 
of a bundle of care consisting of ensuring compliance with four evidence-based measures: 
perioperative normothermia, hair removal, perioperative antibiotic prophylaxis, and discipline 
in the operating room (3). In this study, we found a significant association between early 
revision surgery (within two weeks) and deep-seated SSI development. Future trials should 
be performed on alternative interventions or strategies to reduce SSI after peripheral vascular 
surgery.
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There were some limitations to this retrospective study that should be considered when 
interpreting the results. First, data were based on patients with peripheral arterial obstructive 
disease having peripheral reconstructive surgery. Patients with central reconstructive surgery 
were excluded from the analyses. Results therefore could not be applied to these patients. 
Second, the data were collected from one single center with five vascular surgeons; the 
SSI prevalence could differ from that at other centers. Finally, it should be appreciated that 
this single-center study nonetheless is based on a relatively large sample. There was a good 
collaboration between the medical microbiology department and the surgery department, 
so the presence of a surgical site infection was checked from both sides, limiting the possibility 
of detection bias.
The presence of an SSI is a risk factor for morbidity and death after peripheral vascular surgery. 
Reduction of SSI therefore is an important area for improvement. Early revision surgery in 
the groin, especially that performed within two weeks, is a risk factor for deep-incisional SSI. 
Besides this, the Rutherford class is a risk factor for both superficial and incisional-seated SSI. 
Further research has to be performed on risk stratification models to improve the outcomes 
of patients with peripheral arterial disease.
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AbStRACt
Introduction: The management of surgical site infections (SSI’s) in vascular surgery has been 
challenging over the years. To assess the outcomes associated with the various strategies, we 
performed a review of all SSI’s after elective vascular procedures in patients with moderate to 
severe peripheral arterial disease in a single centre hospital. 
methods: All patients with a SSI after peripheral vascular surgery were retrieved from a 
database on Surgical site infections (SSI)-surveillance after vascular surgery between March 
2009 and January 2012. At admission, all patients were approached by microbiological 
wound sampling and empirical start of antibiotics. Further wound management was based 
on personal experience and preference of the attending vascular surgeon. Endpoints 
were treatment success (complete wound healing while staying alive and without major 
amputation), survival and major amputation during one year follow up.
Results: A total of 40 patients with a SSI were identified (60% superficial SSI and 40% deep 
SSI). In 92% of the patients with a superficial SSI’s were successfully treated with adjusted 
antibiotics and incisional drainages. In the contrast, 25% of the patients with deep-SSI’s were 
successfully treated. No particular treatment was more successful than the others. 
Conclusion: Adjusted antibiotic use and adequate wound drainage are sufficient strategies 
for superficial SSI management. The management of deep-SSI’s is a challenging undertaking 
and future research on indications and timing of these wide arrays of treatment options is 
suggested. 
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IntROduCtIOn
Surgical site infections (SSI’s) are rare but serious complications after vascular surgery resulting 
in an increased risk for morbidity and mortality(1). The consequences are worse when a 
prosthetic graft is involved, e.g. anastomotic-bleeding, reinfection which eventually leads to 
high amputation rates, sepsis and mortality. Besides prevention, also proper management of 
these SSI’s are important for better patient outcomes.
The management of SSI’s in vascular surgery has been challenging. Many treatment strategies 
of infected grafts have been suggested in the literature. Complete removal of the graft with 
extra-anatomic reconstruction with in situ or antimicrobial-impregnated replacement were 
traditionally considered as the ‘golden standard’ (2-4). More recently, the focus has shifted 
towards graft preservation and the previously mentioned strategies are considered to be 
associated with increased morbidity and mortality(5). Several successful graft preservation-
strategies are mentioned like, muscle flaps and negative pressure wound therapies with or 
without muscle flaps (6-9). 
To assess the outcomes associated with the various strategies, we performed a review of all 
SSI’s after elective vascular procedures in patients with moderate to severe peripheral arterial 
disease in our clinic. 
PAtIEntS And mEthOdS 
All patients with peripheral arterial disease (PAD) who developed a SSI after a peripheral 
vascular surgery were retrieved from a prospectively collected database on SSI-surveillance 
after vascular surgery between March 2009 and January 2012 in the Amphia Hospital, Breda, 
the Netherlands(1). Patients were selected based on operation codes corresponding with 
endarterectomy of the femoral artery and peripheral bypass surgery (Figure 1). 
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figure 1. Flowchart of the patient population. 
Procedures were performed in an institution with five vascular surgeons. All patients received 
duplex ultrasound or magnetic resonance angiography (MRA) to determine peripheral arterial 
disease. All patients received Cefazolin intravenously as preoperative antibiotic prophylaxis 
(10). Whenever possible, autologous grafting was performed. Alternatively an expanded 
polytetrafluoroethylene (ePTFE) pre-cuffed Dynaflo® or Distaflo® was used (11). Alternative 
patches for endarterectomies were bovine patches (vascu-Guard®).
Postoperative follow-up examinations include ankle-brachial pressure index, duplex 
ultrasound and surgical wound examination, routinely. 
Registration of SSI`s was performed by dedicated and specifically trained infection control 
personnel routinely performed the surveillance (12). Post-discharge surveillance was 
performed on all patients until 6 months after the date of the procedure. The presence of an 
SSI was ascertained by a microbiologist and a vascular surgeon. Surgical site infections (SSI), 
defined according to the criteria of the Centers of Disease Control (13). 
Although no standard protocol for treatment of vascular SSI’s is present in our hospital, 
the general approach for SSI treatment includes; microbiological wound sampling and 
empirical start of antibiotics (amoxicillin/clavulanic acid or other antibiotics based on earlier 
microbiological cultures). Antibiotic use was adjusted based on the microorganism cultured 
and its antibiogram. Further wound management was based on personal experience and 
preference of the attending vascular surgeon. 
Patient characteristics included age, gender, the American Society of Anaesthesiologists 
(ASA)-score, body mass index (BMI), diabetes mellitus, chronic obstructive pulmonary disease 
(COPD), chronic kidney disease, history of smoking, Rutherford classification, cerebrovascular 
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disease, surgical procedures, opening of wounds for drainage, graft removal, use of antibiotics, 
duration of antibiotic usage, the use of synthetic grafts (bovine patches (vascu-guard®) or 
ePTFE bypasses), amputation and death within 6 months after initial procedure were collected 
from the patient records. 
The primary endpoint was success of treatment. This was defined as complete wound 
healing objectified by a vascular surgeon without major amputation or death during follow 
up. Secondary endpoints were survival and major amputation. Follow up was performed 
until 1 year after the initial procedure. Continuous variables were expressed in means with 
standard deviations (SD). Whenever applicable differences between superficial and deep-
SSI were analysed using chi-square, Fisher’s exact or independent student-t tests. Statistical 
analyses were done using the SPSS® software program version 20 (IBM, Armonk, New York, 
USA). P-values below 0·05 were considered to denote statistical significance. 
RESultS 
A total of 40 patients, mean age 72 ± 10.3 years, were identified with a SSI after vascular 
surgery because of PAD during the study period. Most patients were male (65%), smokers 
(60%) and classified with ASA-classification 3 or 4 (80%). Twenty patients (50%) suffered from 
diabetes mellitus and 12 patients (30%) from chronic renal disease (Table 1). 
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table 1. Patient characteristics and comorbidities prior to revascularization.
Characteristics total 
(n = 40; (%))
Superficial SSI
(n = 24)
deep-SSI 
(n = 16)
P-value
Gender
  Male
  Female
Age
  Mean
  (SD), years
BMI
  <30 (non-obese) 
  >30 (obese)
ASA-classification
  Classification 2
  Classification 3-4
Comorbidity
  Arterial hypertension
  Diabetes
  History of smoking
  Cardiac disease
  COPD
  Chronic kidney disease 
  Cerebrovascular disease
26 (65)
14 (35)
72
(10.3)
31 (78)
9 (22)
8 (20)
32 (80)
24 (60)
20 (50)
24 (60)
21 53)
9 (22)
12 (30)
10 (25)
17
7
72
(8.1)
17
6
4
20
16
13
14
13
5
5
4
9
7
73
(13.2)
14
2
4
12
8
7
10
8
4
7
6
0.34a
0.68b
0.22a
0.52a
0.29a
0.52a
0.79a
0.80a
1.00c
0.12c
0.16c
ASA = American Society of Anesthesiologists; BMI = Body Mass Index; a = Pearson χ2-test; b = Independent Student’s 
T-test; c = Fisher’s Exact Test.
table 2. Procedure characteristics.
Characteristics total 
(n = 40)
Superficial SSI
(n = 24)
deep SSI
(n = 16)
P-value
Rutherford classification
  Class 3
  Class 4
  Class 5/6
Pre-procedural information 
  Redo
  Presence synthetic graft 
Operation
   Endarterectomy
   Supragenicular bypass
   Infragenicular bypass
   Femorocrural bypass
Synthetic grafts  
    Patch
    ePTFE
Vascular reintervention during follow up
3
15
22
16
7
8
13
5
14
23
8
15
4
3
12
9
7
3
6
7
4
7
10
6
4
0
0
3
13
9
4
2
6
1
7
13
2
11
4
0.26b
0.06b
0.00a
0.09a
0.41b
0.44b
0.73a
0.63c
0.50a
0.01a
0.02b
a = Pearson χ2-test; b = Fisher exact-test.
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The indication for surgery was in most cases critical limb ischemia (CLI; Rutherford 
classification 4-6). Pre-procedural information reported 16 patients (40%) with a previous 
vascular procedure and 7 patients (17.5%) with a previous implanted synthetic graft. Finally, 
32 patients had peripheral bypass surgery (80%) (Table 2).   
Superficial SSI
A total of 24 patients were identified with a superficial SSI (Supragenicular: 7 procedure; 
infragenicular 4 procedure; femorocrural: 7 procedures; endarterectomy: 6 procedures). 
No significant difference of patient characteristics were seen between superficial SSI and a 
deep SSI (Table 1). Most patients had surgery because of CLI. In 10 of the 24 patients with a 
superficial SSI, a synthetic graft was implanted (6 patch; 4 ePTFE) (Table 2). 
The 24 superficial SSI’s were identified after an average of 24±19.3 days (Table 3). Most of the 
isolated microorganisms were Staphylococcus aureus and the most chosen antibiotics were 
β – lactams (Table 4 and 5). 
table 3. Postoperative outcome.
total 
(n = 40)
Superficial SSI
(n = 24)
deep SSI
(n = 16)
P-value
Time to SSI*
Anastomotic bleeding 
LOS*
Major amputation
Mortality 
   <30 days
   <6 months
Success of treatment
36 (55.7)
5
28 (26.7)
9
1
6
26
 24 (19.3)
      0
20 (18.7)
1
0
1
22
54 (83.3)
5
40 (32.4)
8
1
5
4
0.10c
0.00b
0.02c
0.00b
0.22b
0.02b
0.00a
LOS = length of hospital stay; a = Pearson χ2-test; b = Fisher exact-test; c = Independent student-t test, * mean in days 
±SD.
table 4. Antibiotics used for SSI treatment.
Choice of antibiotic total 
(n = 40)
Superficial SSI
(n = 24)
deep SSI
(n = 16)
β – lactams 
Aminoglycosides 
Macrolides 
Quinolones 
Vancomycine
Sulfonamides 
36
1
6
10
2
2
20
0
4
4
0
1
16
1
2
6
2
1
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No other procedures were performed after the initial procedure to improve vascular status. 
In 23 out of 24 (96%) cases the wound was opened for drainage. Twenty one patients with a 
superficial SSI received antibiotics (oral and/or parental) for an average period of 16±13.9 days. 
Two patients were successfully treated with negative pressure wound therapy after drainage 
and debridement. No other surgical procedures were performed to improve wound healing 
(Table 6). 
table 5. Microbiology of SSI cultures.
Isolated microorganism total 
(n = 40)
Superficial SSI
(n = 24)
deep SSI
(n = 16)
Staphylococcus aureus
Mixed flora
Enterococcus cloacea 
Proteus mirabilis
Group G beta-hemolytic streptococcus 
Pseudomonas aeruginosa 
Corynebacterium species 
Enterococcus faecalis 
Escherichia coli 
Streptococcus agalactiae 
Citrobacter freundii
Enterococcus faecium 
Proteus vulgaris 
Bacillus cereus
Morganella morganii
Streptococcus pyogenes
Klebsiella pneumoniae 
18
15
4
4
4
4
2
2
2
2
1
1
1
1
1
1
1
12
11
1
3
2
1
1
1
1
0
0
0
0
0
1
1
1
6
4
3
1
2
3
1
1
1
2
1
1
1
1
0
0
0
Twenty-two patients (92%) were successfully treated for superficial SSI’s (complete wound 
healing while amputation free and alive). During 6 months follow up one patient died at the 
intensive care unit after an unsuccessful resuscitation because of congestive heart failure at 
the day of admission. One patients had undergone a major amputation because of end stage 
vascular disease. The average length of hospital stay was 20±18.7 days including potential 
re-admissions (Table 3).  
deep-SSI
For basic patient characteristics see table 1. Sixteen patients with a deep-SSI were identified 
and all had critical limb ischemia (Supragenicular: 6 procedure; infragenicular 1 procedure; 
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femorocrural: 7 procedures; endarterectomy: 2 procedures). Pre-procedural information 
reported 9 patients (56%) with a previous vascular procedure and 4 patients (25%) with a 
previous implanted synthetic graft. A synthetic graft was implanted in 13 of the 16 patients 
with a deep-SSI (2 patch; 11 ePTFE). Before deep-SSI development, 4 patients (25%) had 
another vascular procedure during follow up (Table 2).
All deep-SSI’s were identified after an average of 54±83.3 days. All wounds were opened for 
drainage. Most of the isolated microorganisms were Staphylococcus aureus (n = 6; 38%), in 
three wounds Pseudomonas aeruginosa was cultured (table 5). All patients started with β – 
lactam antibiotics which were adjusted to the results of culture when appropriate (Table 4). 
The mean duration of antibiotic therapy (parental and/or oral agents) was 41±43.6 days and 
was significantly longer than in the superficial SSI group. One bovine patch was removed 
resulting in a successful treatment. One Sartorius muscle flap was used resulting in a treatment 
failure. Negative pressure wound therapy was used in 4 patients. Of these patients, one patient 
had a complete wound healing while staying alive and amputation free. During follow-up, 5 
patients (31%) developed a septic bleeding because of infection after which the bypass was 
removed. In eight out of twelve patients the synthetic bypass was removed (5 (42%) totally; 
3 (25%) partly). In one of these patients a successful treatment was accomplished (table 6). 
Finally, four patients (25%) with a deep-SSI were successfully treated. Eight patients had a 
major amputation after deep-SSI development. After six months 5 patient died (31%). Three 
patients died because of sepsis. The other 3 patients died in the nursing home after they 
decided to stop all medical treatment because of high age and/or other comorbidities. The 
average length of hospital stay was 40±32.4 days including potential re-admissions (Table 3). 
table 6. Treatment strategies during follow-up.
Choice of treatment total 
(n = 40)
Superficial SSI
(n = 24)
deep SSI
(n = 16)
P-value
Wound drainage
Antibiotics used
Total duration antibiotics*
Negative pressure wound therapy
Muscle flap
Patch removal
Bypass removal
    Partial 
    Total  
39
37
26 (31.5)
6
1
1
3
5
23
21
16 (13.9)
2
0
0
0
0
16
16
41 (43.6)
4
1
1
3
5
0.41a
0.14a
0.014c
0.20b
0.40b
0.40b
0.06b
0.01b
a = Pearson χ2-test; b = Fisher exact-test; c = Independent student-t test, * mean days ±SD.
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dISCuSSIOn 
The purpose of this article was to review the treatment of all SSI’s in patients with PAD in 
our clinic. Wound drainage and the use of adjusted antibiotics were adequate therapies for 
treatment of superficial SSI’s in this study. Clinical observation is suggested when prosthetic 
grafts are involved. Treatment of superficial SSI in the outpatient clinic is also applicable in 
carefully selected patients. Deep-SSI’s were serious complications after vascular surgery with 
high mortality and amputation rates compared to superficial SSI’s. No particular treatment was 
more successful than the others in this study. Considering the high rate of treatment failure 
with alternative approaches, complete graft removal could be the best choice for treatment.
The management of vascular SSI’s demonstrates to be a challenging undertaking. Several 
successful graft preservation-strategies are mentioned like negative pressure wound therapies 
with or without muscle flaps (6-9). In this study, negative pressure wound therapy was only 
successful for superficial SSI treatment (2 patients). In patients with deep-SSI, one out of four 
patients treated with negative pressure wound therapy was treated successfully. Besides this, 
we also observed anastomotic-bleedings in 5 patients with a deep-SSI during follow up. This 
should be taken into account when considering negative pressure wound therapy in patients 
with deep-SSI especially when prosthetic grafts are used(14). 
There was one patient who underwent Sartorius muscle flap coverage for graft infection 
treatment. Despite successful wound healing, failed patency resulted in a major amputation. 
Several articles have demonstrated the success of muscle flap coverage of infected grafts in 
the literature (8, 9, 15-17). One study demonstrated prophylactic muscle flaps in groin incisions 
to be effective in reducing wound-related complications(9). They suggested to use these 
muscle flaps in patients with certain high risk comorbidities to reduce SSI development. This 
could contribute to the reduction of SSI. However, because of its retrospective character, future 
prospective studies and the development of risk stratification models should be performed to 
evaluate the effect of prophylactic muscle flaps in these particular patient populations. 
Treatment success also depends on the microorganism creating the infection. Pseudomonas 
aeriginosa is a well-known cause of graft failure in literature (18). Other articles demonstrated a 
success in treating this microorganism using negative pressure therapies and acetic acid(7). In 
our series we observed four patients with Pseudomonas aeruginosa. One patient was clinically 
treated with antibiotics and wound drainage but lost to follow up after discharge. Another 
patient was successfully treated with negative pressure therapy for 17 days. In another patient 
P. aeruginosa was cultured from a superficial SSI and initially treated on the outpatient clinic 
with wound drainage and antibiotics but was eventually admitted because of severe pain of 
the wound. After admission the wound was successfully treated. Finally the last patient with a 
deep-SSI had several anastomotic bleedings resulting in bypass removal and major amputation. 
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Complete graft removal with extra-anatomic reconstruction, in situ or antimicrobial-
impregnated replacement have been considered as the ‘golden standard’ (2-4). In our series 8 
(3 partly and 5 totally removed) from the 11 infected grafts (deep-SSI; ePTFE) were removed 
because of sepsis or anastomotic bleeding. Only one of these 8 patients achieved a full 
treatment success. All the other patients had either a major amputation or died. Complete 
graft removal could be the only solution for deep-SSI treatment but, because of the small 
numbers and study design, results should be carefully interpreted. On the other hand, a 
synthetic graft infection is a risk factors for undergoing major amputation because of the 
underlying PAD(19). Graft removal could therefore have serious consequences. Preventative 
measures and careful patient selection is of the essence to reduce these infections in the 
first place. Besides the retrospective character, the main limitation of this study is the wide 
variety of treatment strategies used for deep-SSI treatment. Therefore, no conclusions can be 
made about the superiority of a specific treatment above the other. On the other hand, the 
occurrence of a SSI after vascular surgery is relatively rare. A study population of 40 patients 
with PAD and a SSI is therefore relatively large. By reviewing these SSI treatment results, we 
tried to demonstrate that the treatment of deep-SSI in patients with PAD is still a challenge. 
Finally, the numbers of synthetic graft infections in this report seems to be relatively large. It 
should be taken into account that this observational study only includes patients with a SSI. 
In a previously published report we described an overall SSI rate of 10.4% and a deep-seated 
SSI rate of 3.5% which is comparable to the literature(1). 
In conclusion, the management of SSI’s in vascular surgery demonstrates to be challenging 
especially for deep-SSI management. Many effective treatment strategies of SSI’s are 
suggested in literature but their precise indication remains unclear. Also in this cohort no 
clear treatment strategies were present for deep-SSI management and many treatment 
options were performed based on the surgeons experience. Future prospective studies have 
to be performed to evaluate the effect, indication and timing of specific treatment options 
for deep-SSI’s in patients with PAD. Also better prediction models on patient outcome after 
deep-SSI development could attribute to better patient outcome. 
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SummARy,  GEnERAl d ISCuSSIOn 
And futuRE PERSPECtIVES
Epidemiologic data predict a significant increase in the number of patients with CLI within 
the next decades (1-3). Synchronous to this, an increase of vascular procedures is expected. 
In general, surgical interventions performed in this particular patient group is associated with 
potentially severe adverse events influencing the outcome. Providing insights of the outcome 
of specific procedures is an important topic in today’s medicine. Results can be used to detect 
shortcomings, evaluate new and old treatment modalities and initiate new research projects. 
Moreover this will increase transparency for physicians, hospitals and patients. In this thesis, 
Peripheral vascular surgery: an appraisal of various clinical outcome measures, the outcome of 
a variety of daily-performed surgical procedures in the vascular clinic of the Amphia hospital 
(Breda, the Netherlands) was studied. 
OutCOmE AftER PER IPhERAl VASCulAR SuRGERy
Post-procedural success of a vascular procedure is among others determined by a manually 
measured ABI in our clinic (2). This measurement is concerned operator dependent and time-
consuming (4). The use of an automated ABI device could resolve these disadvantages in 
postoperative care. The applicability of such a device has been demonstrated in the general 
population for PAD screening (5-9) but has not been used in postoperative ABI measurement. 
In Chapter 2 the clinical applicability of an automated ABI device was compared to the 
manual method for determining the ABI after vascular surgery. This study demonstrated a 
high failure rate in ABI measures of the device with a structural higher ABI value compared to 
the manual method. Additionally, the odds of the automated method not producing a valid 
ABI-value was significantly influenced by gender (females to males OR 10.74 (95 % CI: 1.78-
65.0; p = 0.010)) and the manual-measured ABI-value (OR 1.24 (95 % CI: 1.02-1.52; p = 0.035) 
per 0.1 point decrease in ABI-value). The use of an automated ABI device seems not clinically 
applicable in postoperative ABI-measurement. 
Important outcome parameters in peripheral vascular surgery are patency- and limb salvage 
(2, 10). In Chapter 3 the long-term results of pre-cuffed ePTFE and autologous vein bypass 
grafts were studied. Despite the advantage of a refined distal cuff of the pre-cuffed ePTFE 
grafts, the patency rates of the autologous vein grafts were significantly better. The use of a 
vein graft in peripheral vascular surgery remains the first choice conduit (2). With respect to 
limb salvage, the choice for a pre-cuffed ePTFE graft for peripheral bypass surgery seems to 
be reasonable in the absence of an adequate vein. 
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In an attempt to improve patency of synthetic bypasses the heparin bounded ePTFE (HePTFE) 
graft was developed. The results of these bypasses are conflicting in the literature, reporting 
excellent patency rates (11) but also comparable patency rates as ePTFE grafts (12, 13). The 
potential advantage of this bypass has therefore not yet been demonstrated. 
Due to various reasons; e.g. previous lower extremity bypass procedures, coronary bypass 
grafting, trauma or poor vein quality, many patients do not have an adequate limb vein (14, 
15) often forcing the surgeon to choose for synthetic conduits. The use of arm vein grafts 
could contribute to better alternatives in the absence of an adequate limb vein (16) and could 
be an acceptable intermediate step before choosing for synthetic conduits (17, 18). In our 
clinic the use of arm vein grafts for peripheral bypass surgery is not commonly used because 
of superficial veins of the upper arm are fragile and tedious to harvest, resulting in large 
wounds. Additionally those bypasses are known for stenosis leading to more re-interventions 
(17). Despite these disadvantages arm vein grafts could contribute to better patency- and 
limb salvage rates in particular for infragenicular or femorocrural bypass surgery. 
Loss of patency can be caused by an acute occlusion of a bypass or native artery due to 
an embolism or thrombus resulting in acute limb ischemia (ALI) (19, 20). In Chapter 4 the 
outcome of intra-arterial thrombolysis and thromboembolectomy were compared. Both one-
year primary patency- and limb salvage rates were not significantly different. However, the 
one-year mortality rates were significantly higher in the thromboembolectomy group. A wide 
variety of adverse events were registered. Most were procedure related (77% thrombolysis vs 
76% thromboembolectomy), resulting in surgical re-interventions. A considerable amount of 
adverse events resulted in irreversible damage and even death.
In the literature, no evidence in favor of any intervention as the preferred option in terms 
of patency, limb salvage or mortality is described (21). Also in our study, no difference was 
observed. Both interventions are effective in the treatment of patients with ALI. The high 
mortality rate after thromboembolectomy was explained by potential selection bias due to 
the retrospective study design. 
To reduce the systemic effects of thrombolysis, many isolated pharmaco-mechanical 
thrombolysis systems have been developed (22-32). Although these systems are promising, 
most reports about these new techniques are based on case reports or small clinical studies. 
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PREVEntIOn And tREAtmEnt Of SS I 
An important topic in modern health care is the reduction of adverse events. A study, 
performed on adverse events among patients in Dutch hospitals, resulted in the conclusion 
that most adverse events were caused by healthcare management rather than by the patient’s 
underlying disease (33). Surgical site infections (SSI’s) were one of those potentially preventable 
adverse events. In Chapter 5 the effect of the introduction of a bundle of care was studied to 
explore the effect on SSI-reduction after vascular surgery. The results demonstrated an overall 
SSI-rate of 10.4% in our clinic. Both superficial- and deep-seated SSI’s occurred significantly 
more frequent after peripheral vascular procedures compared to central vascular procedures. 
If a superficial - or deep-seated SSI occurred, it resulted in a prolonged length of hospital stay 
of 18 days (superficial SSI) and 37 days (deep-seated SSI) demonstrating the importance of 
reducing these adverse events. After all, the implementation of the bundle resulted in a 51% 
reduction of SSI’s in the last year, compared to the first year. 
There are some contradictory results of a bundle of care on SSI reduction in the literature. A 
positive effect of using a bundle of care to reduce SSI was reported in studies on catheter- 
and ventilation related infections on the ICU (34, 35). In other studies after colorectal surgery, 
the effects of such a bundle could not be demonstrated (36, 37). The main criticism on 
those studies is that the bundle was mainly based on technical adjustments, which did not 
encourage a structural improvement in the overall surgical process to create a safety culture. 
A comparable study to our study was performed in our clinic after colorectal surgery which 
also demonstrated a reduction of SSI’s after implementation of the bundle (38). We therefore 
recommend the implementation of this bundle on a large scale. 
Redo-surgery is not an exception in the time-course of patients with PAD. In many of 
these procedures, a groin incision is involved. The interval between these procedures can 
also vary from no previous procedure, to procedures within days, months and even years. 
In the literature, a groin incision is a risk-factor for SSI development (39). In Chapter 6 the 
occurrence of SSI after vascular surgery performed in different time-intervals was studied. 
The results demonstrated a significant linear trend effect of the groin incision interval on the 
development of deep-seated SSI’s: the shorter the interval, the higher the event rate (HR 1.5 
per category, 95% CI 1.1-2.1, p = 0.022). This suggests early revision surgery to be a risk factor 
for deep-SSI development. The incision interval had no significant effect on the development 
of superficial SSI’s. Besides the incision interval, increased Rutherford-classification was a 
significant risk factor for superficial- as well as for deep-seated SSI development. 
Misleading results could occur when vascular institutions are compared to each other based 
on SSI-rates, without taking the patient population into account. For example, the SSI-rate is 
expected to be much higher in a vascular population consisting of patients with deteriorated 
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stages of PAD. Also the amount of redo-procedures are assumed to be higher in this patient 
group compared to a vascular population consisting of patients with less deteriorated severe 
stages of PAD. 
Alternative procedures to avoid dissection of a previously operated groin, like the use of 
endografts in creating an endoluminal bypass, are described in the literature (40). Results 
suggested this strategy to be a valid alternative although the level of evidence was low 
because of the small numbers of patients. This could also have a potential positive effect on 
SSI reduction and should be evaluated in future prospective studies performed on a larger 
population. 
Both prevention and treatment of SSI’s are important for improving patient outcome and 
quality of care. In the literature, a wide variety of treatment options have been described, 
all demonstrating good clinical results after treatment of SSI (41-47). Some studies suggest 
complete removal of prosthetic grafts, with replacement of new antimicrobial grafts or extra-
anatomic reconstruction, others suggest graft preservation. Most of these studies are based 
on a selected patient populations and the indication for each different treatment strategy is 
often unclear. In Chapter 7 the treatment of all our registered SSI after peripheral vascular 
surgery were studied. Wound debridement and the use of adjusted antibiotics seemed 
adequate treatment strategies in managing superficial SSI. The treatment strategies of deep-
seated SSI were less successful which resulted in many comorbidities and even death. No 
particular treatment was more successful than the others in this study. Considering the high 
rate of treatment failure with alternative approaches, complete graft removal could be the 
best choice for treatment. Future prospective studies have to be performed to evaluate the 
effect, indication and timing of specific treatment options for deep-seated SSI’s in patients 
with PAD. The use of prediction models could contribute to better patient outcomes.  
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futuRE PERSPECtIVES
Patients with CLI are fragile, high-risk patients. Determining treatment strategies solely based 
on patency- and limb salvage rates may not be adequate in improving outcome after vascular 
surgery. 
Due to technological developments and significant morbidity after infrainguinal bypass 
surgery, the use of endovascular interventions are more commonly performed for CLI 
compared to open procedures (48-50). Despite the rapid increase in new techniques 
and devices, results seem not to improve these outcome measures (51). Moreover, the 
interpretation of new techniques are increasingly complex because of the wide variety of 
treatment options in which the results are often overtaken by new developments or insights. 
Patient specific outcome measures are undervalued in clinical studies and mostly based on 
retrospective analyses providing insights into these endpoints (51). Considering the outcome 
of revascularization, limited life expectancy and the possible comorbidities that may arise 
after revascularization attempts, study results should be focused more on these outcome 
measures. In some cases, for example, conservative therapy or a major amputation could also 
be an important treatment strategy in the treatment of CLI (52, 53).
Risk stratification models on the outcome of patients with CLI could contribute to improve 
outcome by better decision-making (51). A few externally validated models already exist 
(54-57). Although these models are promising in predicting outcome of this specific patient 
population, they seem to be based on heterogeneous predictor variables resulting in modest 
predictive abilities (58). 
Besides these risk stratification models, patient related outcome measures (PROMs) could also 
contribute to improving care in this patient population. The aim of PROMs is to capture the 
patient his perspectives of health, illness and the effects of health care interventions (59). 
An earlier report from our clinic demonstrated a significant increase in quality of life (QoL) 
3 month after peripheral bypass surgery which was lost after midterm follow-up (60). They 
concluded no relation between quality of life (QoL) and traditional outcome measurements 
(patency-, limb salvage- and mortality rates). PROMs could add insights of provided care of 
specific procedures or specific patient groups we therefore decided to start a prospective 
study on QoL in the elderly vascular patient with CLI. 
In conclusion, further refinement of risk stratification models and better insights in PROMs 
by prospective studies are important to improve patient outcome. Although, these models 
will never completely predict patient outcome, they can be used to improve patient and 
physician decision making and therefore improve patient outcome. 
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SAmEnVAttInG,  AlGEmEnE dISCuSSIE 
En tOEkOmStPERSPECtIEVEn
In de komende decennia zal naar verwachting het aantal patiënten met kritieke ischemie gaan 
toenemen (1-3). Met deze ontwikkeling zal er ook een toename van vasculaire procedures zijn. 
Het uitvoeren van chirurgische interventies in deze patiënten populatie is geassocieerd met 
potentieel ernstige complicaties. Inzicht verkrijgen in de uitkomsten van bepaalde procedures 
is dan ook een belangrijk onderdeel in de huidige geneeskunde. Resultaten kunnen worden 
gebruikt om tekortkomingen te ontdekken, oude en nieuwe behandelmethodes te evalueren 
en nieuwe onderzoeken te initiëren. Bovendien zorgt het voor transparantie bij zorgverleners, 
zorginstellingen en patiënten. In dit proefschrift, Perifere vaatchirurgie: een beoordeling van 
verschillende klinische uitkomsten, werden uitkomsten van verscheidene vaatchirurgische 
ingrepen, uitgevoerd in het Amphia ziekenhuis, bestudeerd. 
uItkOmStEn nA PER IfERE  VAAtChIRuRGIE 
Het postoperatieve succes van een vaatoperatie wordt in onze kliniek onder andere bepaald 
door een handgemeten enkel/arm index (EAI) (2). Het meten van een handmatige EAI neemt 
veel tijd in beslag en vraagt enige expertise van de persoon die de metingen uitvoert (4). 
Een automatisch EAI apparaat zou hier uitkomst kunnen bieden. In de huisartsenpraktijk 
heeft een dergelijk apparaat al zijn meerwaarde getoond bij het diagnosticeren van perifeer 
arterieel vaatlijden (PAV) (5-9), echter nog niet in het meten van een postoperatieve EAI. 
Dit zou ook het geval kunnen zijn bij het bepalen van een postoperatieve EAI. 
In hoofdstuk 2 werd de klinische toepasbaarheid van een automatisch EAI apparaat 
vergeleken met de handmatige methode na vaatchirurgie. Deze studie liet zien dat het 
apparaat een hoge failure-rate had waarbij het een structureel hogere EAI produceerde 
vergeleken met de handmatige methode. De kans dat het apparaat niet instaat was een EAI 
te produceren werd significant beïnvloed door het geslacht (vrouwen vs mannen OR 10.74 
(95 % CI: 1.78-65.0; p = 0.010)) en de handgemeten EAI-waarde (OR 1.24 (95 % CI: 1.02-1.52; 
p = 0.035) per 0.1 punt afname in EAI-waarde). Het lijkt dan ook dat een automatische EAI 
apparaat niet geschikt is om postoperatieve EAI metingen uit te voeren. 
Belangrijke uitkomstmaten voor het weergeven van bepaalde vaatingrepen zijn patency 
en limb salvage (2, 10). In hoofdstuk 3 werden de lange termijn uitkomsten van pre-cuffed 
ePTFE- en autologe veneuze bypass grafts bestudeerd. Ondanks de aangepaste distale cuff 
van de pre-cuffed ePTFE bypass waren de patency-rates van de autologe bypass grafts 
significant beter. Het gebruik van een veneuze graft is daarom nog steeds de eerste keus in 
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perifere bypasschirurgie. Met het oog op limb salvage is de keuze voor een pre-cuffed ePTFE 
graft te verdedigen bij afwezigheid van een adequate autologe vene. 
In een poging om patency-rates van synthetische bypasses te verbeteren zijn er heparine 
gecoate ePTFE (HePTFE) bypasses ontwikkeld. De literatuur toont echter tegenstrijdige 
resultaten met een studie met excellente patency-rates (11) en studies waarbij er geen verschil 
in patency-rates werd gevonden tussen HePTFE en ePTFE bypasses (12, 13). Een potentieel 
voordeel van deze bypasses is daarom nog niet geleverd. 
Om verschillende redenen (eerdere perifere bypass procedures, coronaire bypass chirurgie, 
trauma of slechte kwaliteit van de vene) kan er bij een patiënt geen bruikbare vene meer 
aanwezig zijn (14, 15). Een arm vene zou een goede tussenstap kunnen zijn voordat er gekozen 
wordt voor een synthetische bypass (16-18). In onze kliniek maken wij sporadisch gebruik van 
arm vene. Doorgaans zijn deze oppervlakkige venen erg fragiel en lastig vrij te prepareren, 
leidend tot een grote wond. Daarnaast hebben deze bypasses meer kans op stenosering, 
resulterend in meer re-interventies (17). 
Het verlies van patency kan worden veroorzaakt door een acute vaatocclusie van een natief 
vat maar ook door een embolus of trombus in een eerder aangelegde bypass wat uiteindelijk 
leidt tot acute ischemie (AI) (19, 20). AI kan worden verholpen middels trombolyse of een 
chirurgische embolectomie. In hoofdstuk 4 werden beide behandelingen met elkaar 
vergeleken met de daarbij opgetreden complicaties. Uit de studie bleek dat zowel de 1 
jaar primaire patency- als de limb salvage-rates niet significant verschilden tussen beide 
behandelmethodes. We zagen wel een significant hogere mortaliteit na chirurgische 
embolectomie. Een grote verscheidenheid aan complicaties werden geregistreerd waarvan 
het leeuwendeel procedure gerelateerd waren (77% trombolyse vs 76% embolectomie), 
leidend tot chirurgische re-interventies. Er werd ook een aanzienlijk aantal complicaties 
geregistreerd die resulteerden in irreversibele schade en zelfs het overlijden van een patiënt.
In de literatuur wordt er geen bewijs geleverd over welke behandelmethode een betere 
uitkomst oplevert ten aanzien van 1-jaar patency, limb salvage of mortaliteit (21). Dit kwam 
ook uit onze studie naar voren. Beide behandelingen hadden een vergelijkbare uitkomst. De 
hogere sterfte na embolectomie werd verklaard door het retrospectieve design van de studie 
waarbij er mogelijk selectie bias heeft plaats gevonden. 
Om het systemische effect van trombolyse te beperken zijn er de afgelopen jaren vele nieuwe 
methodes ontwikkeld die door hun lokale werking tot minder complicaties moet gaan leiden 
(22-32). Alhoewel dit veel belovende methodes lijken te zijn, is het bewijs vaak gebaseerd op 
case reports of kleine retrospectieve studies. 
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PREVEntIE  En bEhAndElInG VAn POStOPERAtIEVE 
WOndInfECtIES  (POWI )
Een steeds belangrijker wordend onderwerp in de hedendaagse gezondheidzorg is het 
reduceren van postoperatieve complicaties. Uit een studie onder Nederlandse ziekenhuizen 
kwam naar voren dat de meeste postoperatieve complicaties werden veroorzaakt door 
zorg gerelateerde handelingen in plaats van patiënt gerelateerde co-morbiditeit (33). 
Postoperatieve wondinfecties (POWI) waren een van deze voorkombare complicaties. 
In hoofdstuk 5 werd het effect van de introductie van een bundel met zorgmaatregelen 
(veiligheidsmanagementsysteem (VMS)-bundel) op POWI-reductie na vaatchirurgie 
bestudeerd. 
De resultaten van deze studie toonden dat in 10.4% van de geopereerde patiënten een POWI 
voorkwam. Zowel oppervlakkige- als diepe-POWI kwamen significant vaker voor na perifere 
vaatchirurgie dan na centrale vaatchirurgie. Als er zich een oppervlakkige- of diepe-POWI 
voordeed, resulteerde dit in een verlengde opnameduur van 18 dagen (oppervlakkige-POWI) 
en 37 dagen (diepe-POWI). Na het implementeren van de VMS-bundel werd er een 51% POWI 
reductie in het laatste jaar ten aanzien van het eerste jaar gezien.
Het gebruik van bundels voor het reduceren van POWI heeft tegenstrijdige resultaten 
opgeleverd in de literatuur. Een positief effect van een dergelijke bundel werd beschreven 
in studies naar de reductie van centrale lijn gerelateerde- en ventilatie gerelateerde infecties 
op de intensive care (34, 35). In andere studies kon dit effect niet worden aangetoond (36, 
37). De gebruikte bundels waren met name toegespitst op technische veranderingen in 
het zorgproces waarbij er geen poging werd gedaan om een veiligheid cultuur te creëren. 
Een vergelijkbare studie als de onze werd verricht in ons ziekenhuis na colorectale chirurgie 
wat ook een significante POWI reductie liet zien na implementatie van de bundel (38). Op 
basis van onze bevindingen concludeerden we dat de bundel zoals gedefinieerd door VMS 
POWI een nuttig hulpmiddel is om een veiligheidscultuur te bewerkstelligen en daarmee de 
kwaliteit van de zorg en de patiëntveiligheid te verbeteren.
Redo-chirurgie is geen uitzondering in het ziektebeloop van patiënten met perifeer vaatlijden. 
Bij veel van deze ingrepen wordt er gebruik gemaakt van een liesincisie. Wanneer redo-
chirurgie geïndiceerd is, kan het interval tussen de primaire operatie en de redo-operatie 
variëren van dagen tot maanden of zelfs jaren. In de literatuur worden liesincisies gezien als 
een riscofactor op het ontwikkelen van POWI (39). In hoofdstuk 6 werd het optreden van 
POWI na redo-chirurgie bestudeerd. De resultaten lieten zien dat een kort tijdsinterval leidde 
tot een hogere kans op het ontwikkelen van een diepe-POWI (HR 1.5 per categorie, 95% CI 
1.1-2.1, p = 0.022). Het incisie interval had geen significant effect op het ontwikkelen van 
oppervlakkige-POWI. 
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Naast het incisie interval was de ernst van het perifeer vaatlijden een risicofactor voor het 
ontwikkelen van zowel oppervlakkige- als diepe-POWI. 
De resultaten van deze studie laten niet alleen zien dat redo-chirurgie een risicofactor 
is voor het ontwikkelen van diepe-POWI maar het laat ook zien dat er verschillen bestaan 
tussen vaatpopulaties. Bijvoorbeeld bij het vergelijken van uitkomsten tussen verschillende 
vaatklinieken is het belangrijk om de samenstelling van de vaatpopulatie hierbij mee te 
nemen. 
Redo-chirurgie is mogelijk te vermijden door alternatieve procedures te hanteren zoals 
endografts om endoluminale bypasses te creëren (40). Deze techniek is beschreven als 
alternatief voor redo-chirurgie zodat dissectie van eerder geopereerd gebied vermeden kan 
worden mogelijk leidend tot een reductie van POWI. De resultaten van deze studie waren 
veel belovend echter gebaseerd op kleine aantallen patiënten. Toekomstig prospectief 
gerandomiseerd onderzoek zou hier uitsluitsel over moeten geven. 
Zowel preventie als de behandeling van POWI zijn belangrijk in het verbeteren van 
patiëntuitkomsten. In de literatuur wordt een uitgebreid palet aan behandelmogelijkheden 
beschreven die goede resultaten laten zien voor de behandeling van POWI (41-47). Enkele 
studies suggereren dat bij een POWI het synthetische materiaal in zijn geheel verwijderd 
dient te worden en vervangen dient te worden door of een in antibiotica gedrenkte graft 
of door extra-anatomische reconstructies. Andere studies suggereren weer tot het behoud 
van het materiaal. Het merendeel van deze studies zijn gebaseerd op geselecteerde 
patiëntengroepen waarbij de indicatie voor dergelijke behandelopties onduidelijk is. In 
hoofdstuk 7 wordt de behandeling van zowel oppervlakkige- als diepe-POWI in onze kliniek 
beschreven. Debridement van de wond en het starten van antibiotica was een adequate 
behandelstrategie voor de behandeling van oppervlakkige-POWI. De behandeling strategie 
van diepe-POWI bleek divers te zijn met weinig succesvolle behandelingen resulterend in 
complicaties en zelfs tot het overlijden van de patiënt. Geen van de behandel strategieën bleek 
succesvoller te zijn dan de ander. Gezien het hoge percentage gefaalde behandelstrategieën 
zou het volledig verwijderen van de graft de beste keuze voor behandeling kunnen zijn. 
Toekomstig prospectief gerandomiseerd onderzoek moet uitwijzen welke strategie het meest 
succesvol is bij de behandeling van diepe-POWI. 
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tOEkOmStPERSPECtIEVEn 
Patiënten met ernstig perifeer arterieel vaatlijden zijn doorgaans hoog-risico patiënten als 
ze geopereerd worden. Het bepalen van een behandeling alleen gebaseerd op patency- en 
limb-salvage rates lijkt niet afdoende in het verbeteren van de uitkomsten van vaatchirurgie. 
Mede door de technologische ontwikkelingen en significante morbiditeit na perifere bypass 
chirurgie, worden er steeds vaker endovasculaire behandelingen verricht in de behandeling 
van PAD (48-50). Ondanks de toename van deze technologische ontwikkelingen lijken de 
resultaten van de behandeling van PAD niet significant te verbeteren (51). Daarnaast is het vaak 
lastig om nieuwe technieken goed in kaart te brengen vanwege de grote verscheidenheid 
aan behandelingen waarbij resultaten vaak al weer worden ingehaald door nieuwe inzichten 
en ontwikkelingen.
Patiënt specifieke uitkomstmaten zijn vaak ondergewaardeerd in klinische studies en vaak 
gebaseerd op retrospectieve studies (51). Resultaten van behandelingen, levensverwachting 
en mogelijke complicaties na een ingreep zouden meer meegenomen mogen worden in 
klinische studies. In sommige gevallen is bijvoorbeeld een conservatief beleid bij ernstig 
perifeer vaatlijden ook een goed te verdedigen (52, 53).
Risico predictiemodellen zouden kunnen bijdragen aan de verbetering van uitkomsten in 
patiënten met PAD door handvaten te bieden bij besluitvorming (51). In de literatuur zijn er 
al een aantal gevalideerde modellen beschreven (54-57), echter bleken deze modellen tot nu 
toe een matig voorspellend vermogen te hebben (58). 
Naast deze risico predictiemodellen zouden PROMs (patient related outcome measures) 
ook kunnen bijdragen aan de verbetering van uitkomst in deze patiënten populatie. PROMs 
omvat resultaten die vanuit het perspectief van de patiënt inzicht geven tot zijn gezondheid, 
ziekte en effect van interventies (59). Een eerdere studie uit onze kliniek toonde al een verschil 
in QoL en traditionele uitkomstmaten (patency-, limb salvage- en mortaliteit) (60). Om dit 
soort inzichten te krijgen bij oudere patiënten zijn we gestart met een prospectieve studie na 
de kwaliteit van leven van de oudere patiënt met kritieke ischemie.  
Tot slot, toekomstige prospectieve studies zullen moeten leiden tot verdere verbetering 
van risico predictiemodellen en een beter inzicht geven in PROMs om zo besluitvorming en 
patiënten uitkomsten te verbeteren. 
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me er in het begin geen voorstelling bij kon maken, heb ik me erin vastgebeten. Het is zeker 
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heeft dan ook geresulteerd in dit proefschrift. Ik wil je bedanken voor alle kansen die je me 
hebt geboden en vooral ook voor het vertrouwen op een goede afloop. Ondertussen ben ik 
in opleiding tot chirurg waarbij ik de komende jaren nog veel van je hoop te leren. 
Dr. G.H. Ho. Beste Gwan, bedankt voor de scherpe feedback en opbouwende kritiek 
met betrekking tot de structuur van de hoofdstukken. Mede dankzij deze correcties is de 
leescommissie een hoop paginavulling bespaart gebleven. Ook is het schrijven me wat beter 
afgegaan maar een native speaker zal ik vrees ik nooit worden. 
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gemis maar bedankt voor de mooie tijd! 
Beste chirurgen van het Amphia ziekenhuis bedankt voor de totstandkoming van dit 
proefschrift en voor de ruimte om mezelf te ontwikkelen als toekomstig chirurg. Ik heb al veel 
mogen leren en doe dat nog steeds elke dag met veel plezier. 
Beste chirurgen van het Erasmus MC bedankt voor het leerzame en leuke jaar als ANIOS 
chirurgie en tot over een paar jaar.
J. Rasenberg en C.E. Zandijk. Beste Jacqueline en Carola, hartelijk dank voor jullie inzet bij het 
regelen van zaken omtrent dit proefschrift. 
J. van Trier. Beste Jan, bedankt voor het opzoeken van artikelen en voor de afleiding tussen 
de eenzame uurtjes door in de bibliotheek van het Amphia ziekenhuis. Ik kom nog wel eens 
een bakkie doen.
Beste collegae, A(N)IOS chirurgie uit het Amphia en Erasmus MC, in dit dynamische en soms 
hectische vak is het heel belangrijk dat je iets voor elkaar over hebt om verder te komen. 
Bedankt voor de collegialiteit en de gezelligheid zowel binnen als buiten het werk. 
Beste overige collegae uit het Ampia; verpleegkundigen van afdeling 46, vaatlaboranten, 
verpleegkundig specialisten, medewerkers van de operatie kamer, medewerkers van 
Laboratorium voor microbiologie en infectiepreventie (LMI), Amphia academie, bedankt voor 
de bijdrage aan dit proefschrift. 
Mijn paranimfen, L.R. Wong-Lun-Hing en J.W. Raats. Beste Luc, goede vriend. Ik ken je 
ondertussen al meer dan 10 jaar waarbij we maten zijn door dik en dun. Je positieve levenslust 
en onuitputtelijke ondernemingsdrang geven mij energie de dingen te doen die ik doe. Voor 
goed advies als ook voor mooie feestjes kan ik bij je terecht. Voor mij is het daarom dan ook 
logisch dat je naast me staat tijdens m’n verdediging. 
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Beste Jelle, vriend en tevens collega. We kennen elkaar vanuit het Bredase alwaar we beiden 
ons door de onderzoeksprojecten heen worstelden. We hebben mooie tijden meegemaakt 
waarin we elkaar hebben bijgestaan. Jou adviezen hebben zeker bijgedragen aan dit 
proefschrift. Ik wens je een mooie tijd in het Maasstad en kijk uit naar je promotie. Voor nu kan 
ik me geen betere paranimf voorstellen om mij bij te staan tijdens de verdediging. 
Beste familie en vrienden. Indirect bedankt voor de steun en begrip voor de totstandkoming 
van dit proefschrift. Ik heb geprobeerd overal zoveel mogelijk bij aanwezig te zijn maar er zijn 
ook momenten geweest die ik heb moeten laten schieten. Voor mij was dit onvermijdelijk 
gezien dit proefschrift in mijn eigen tijd moest worden gerealiseerd maar ik realiseer me dat 
daar ook begrip voor moet zijn.
Lieve familie de Wit. Bedankt voor jullie warmte en gezelligheid. Zonder jullie luisterend oor 
was dit proefschrift nog lang niet afgerond.
Lieve opa en oma Maatman, oma van der Slegt. Alles begint bij een goede fundering zullen 
we maar zeggen. Jullie verhalen over het verleden zijn met geen mogelijkheid meer te 
spiegelen aan de huidige tijd. Grote gezinnen waarbij er keuzes gemaakt moesten worden 
of er überhaupt ruimte was voor het doen van een opleiding dat was allemaal heel anders 
toen. Toch denk ik dat mede door jullie inzet en opofferingen de basis is gelegd om volgende 
generaties verder te laten komen en dat is noemenswaardig. Ik betreur het zeer dat oma van 
der Slegt deze promotie niet kan meemaken en hoop dat opa en oma Maatman aanwezig 
kunnen zijn als hun lichamelijke maar ook geestelijke gezondheid dat toelaat.
Gerben en Femia, Marleen en Wesley, lieve pap en mam. Bedankt voor de steun bij het 
schrijven van dit proefschrift. We hebben de laatste jaren een mindere periode gekend waarin 
er veel van ons werd gevraagd. Gelukkig lijkt deze periode nu achter de rug te zijn en kunnen 
we ons weer richten op de toekomst. We zijn hierdoor ondanks de fysieke afstand dichter tot 
elkaar gekomen. Lieve pap en mam zonder jullie steun zou dit alles nooit gerealiseerd zijn. 
Bedankt voor de altijd goede zorgen en adviezen. Zutphen is en blijft voor mij thuiskomen! 
Last, but not least. Lieve Sophie, lieve Jopie. Dat jij het überhaupt met mij kan uithouden vind 
ik een wonder, ik weet namelijk dat ik veel van je vraag. Ik bewonder je geduld en begrip voor 
de afgelopen jaren. Je positieve instelling en relativeringsvermogen hebben ertoe geleid dat 
dit allemaal is gelukt, je betekent alles voor me!
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Name PhD student: Jasper van der Slegt
Erasmus MC Department: Surgery
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